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ABSTRACT 
 
 
 
Garner, Matthew L. M.S., Purdue University, December 2012. Design, Synthesis and 
Study of DNA-Targeted Benzimidazole-Amino Acid Conjugates. Major Professor: Eric C. 
Long. 
 
 
The DNA minor groove continues to be an important biological target in the 
development of anticancer, antiviral, and antimicrobial compounds.  Among agents that 
target the minor groove, studies of well-established benzimidazole-based DNA binders 
such as Hoechst 33258 have made it clear that the benzimidazole-amidine portion of 
these molecules promotes an efficient, site-selective DNA association.  Building on the 
beneficial attributes of existing benzimidazole-based DNA binding agents, a series of 
benzimidazole-amino acid conjugates was synthesized to investigate their DNA 
recognition and binding properties.  In this series of compounds, the benzimidazole-
amidine moiety was utilized as a core DNA “anchoring” element accompanied by 
different amino acids to provide structural diversity that may influence DNA binding 
affinity and site-selectivity.  Single amino acid conjugates of benzimidazole-amidines 
were synthesized, as well as a series of conjugates containing 20 dipeptides with the 
general structure Xaa-Gly.  These conjugates were synthesized through a solid-phase 
synthetic route building from a resin-bound amino acid (or dipeptide).  The synthetic 
steps involved: (1) the coupling of 4-formylbenzoic acid to the resin-bound amino acid 
(via diisopropylcarbodiimide and hydroxybenzotriazole); followed by (2) introduction of a 
3,4-diaminobenzamidoxime in the presence of 1,4-benzoquinone to construct the 
benzimidazole ring; and, finally, (3) reduction of the resin-bound amidoxime functionality 
to an amidine via treatment with 1M SnCl2·2H2O in DMF before cleavage of final product 
from the resin.  The synthetic route developed and employed was simple and 
straightforward except for the final reduction that proved to be very arduous.  All target 
compounds were obtained in good yield (based upon weight), averaging 73% mono-
amino acid and 78% di-amino acid final compound upon cleavage from resin.  
xiv 
Ultimately, the DNA binding activities of the amino acid-benzimidazole-amidine 
conjugates were analyzed using a fluorescent intercalator displacement (FID) assay and 
calf thymus DNA as a substrate.  The relative DNA binding affinities of both the mono- 
and di-amino acid-benzimidazole-amidine conjugates were generally weaker than that of 
netropsin and distamycin with the dipeptide conjugates showing stronger binding 
affinities than the mono-amino acid conjugates.  The dipeptide conjugates containing 
amino acids with positively charged side chains, Lys-Gly-BI-(+) and Arg-Gly-BI-(+), 
showed the strongest DNA binding affinities amongst all our synthesized conjugates. 
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CHAPTER 1. STRUCTURE OF B-FORM DNA AND MINOR GROOVE RECOGNITION 
BY LOW MOLECULAR WEIGHT COMPOUNDS 
 
1.1. Overview 
The DNA minor groove has been an important focus of chemical and biological 
studies since the elucidation of the structure of DNA and an understanding of the role of 
DNA in the life cycle of a cell.  The interaction of small molecules with DNA is also a 
prolific area of study because many therapeutically important molecules bind reversibly 
to nucleic acids.1-6  It is commonly believed that minor groove binding compounds 
disrupt normal cellular functions by binding near or at promoter regions of genes, altering 
transcription7 or disrupting DNA replication.  Thus, much effort has been directed toward 
the discovery of low molecular weight compounds that recognize and bind to DNA due to 
their potential use as anticancer, antiviral, and antimicrobial drugs.7-10   In addition, the 
development of sequence-specific and sequence-selective DNA binding molecules is a 
research goal that is important for understanding nucleic acid molecular recognition due 
to the ability of these agents to act as nucleic acid conformational probes and 
footprinting reagents.11,12  In general, low molecular weight ligands recognize DNA using 
a combination of weak intermolecular forces such as electrostatics, van der Waals 
forces, and hydrogen bonding; DNA binding can ultimately occur through ligand 
interactions with the minor groove, phosphodiester backbone, and stacked Watson-Crick 
base pairs.   
As will be discussed, the structural basis for the design of many man-made DNA 
minor groove binding ligands originates from naturally occurring peptide-based 
compounds such as netropsin, distamycin, actinomycin, and echinomycin.13-16  These 
compounds have provided a starting point for many drug design efforts including 
synthetic polyamides.17  Also, benzimidazole derivates18 have displayed exceptional 
DNA binding abilities and may provide a useful moiety for drug design.  Some important 
features of molecules that bind to the minor groove of B-DNA like those mentioned 
above are: (1) a crescent shape complementary to the curvature of the minor groove; (2) 
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positive charges that enhance electrostatic interactions; (3) inward-facing hydrogen-
bonding groups for sequence recognition; and (4) an unfused heterocyclic structure that 
allows flexible structural optimization of the compound for minor groove interactions.19  
These guidelines have aided in the design of minor groove binding heterocycles with 
strong minor groove binding interactions and biological activities.20-21  While we note the 
importance of shape complementarity, more recent studies also emphasize that the 
shapes of compounds do not have to exactly match the curvature of the minor groove to 
yield strong sequence-specific binding, as well as the usefulness of nitrogen containing 
heterocycles for minor groove recognition.22  All of these factors were considered in the 
design of our minor groove binding agents to be described herein. 
This thesis will describe a series of mono- and di-amino acid-benzimidazole-
amidine conjugates designed to target the minor groove of B-form DNA.  A phenyl-
benzimidazole core structure will be included to provide hydrogen-bonding sites as well 
as allowing an overall molecular curvature that closely resembles that of the minor 
groove.  In addition, by introducing amino acids, we will place in position: (1) amide 
bonds that can serve as auxiliary hydrogen-bonding sites to interact with the DNA minor 
groove, and (2) side-chains that introduce structural and chemical diversity.  Finally, an 
amidine group will provide a positively charged moiety that can interact electrostatically 
with the negatively charged phosphodiester backbone of DNA.  Positively charged 
moieties are usually attracted to A/T-rich regions of DNA that have a slightly increased 
electrostatic potential than regions of G•C base pairs.  
 
1.2. Introduction to DNA Structure 
 
1.2.1. Overview 
 The “Central Dogma of Molecular Biology” (Figure 1.1) outlines the role of DNA 
in living organisms23 and the role of DNA in replication and protein expression.  DNA 
contains all the genetic information that controls the synthesis and regulation of protein 
expression in a cell.  DNA has two main functions: (1) to provide a template for its own 
replication during cell division and (2) to direct transcription of complementary strands of 
messenger ribonucleic acid (mRNA) and other RNAs.24  Upon the initiation of protein 
expression, DNA is initially transcribed into an mRNA template that is processed and 
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transported to a ribosome where the mRNA is used as a direct read-out template 
containing a triplet code specifying the amino acids of a specific protein.  DNA thus 
encodes all of the sequence information of a protein and dictates the sequences where 
proteins bind to regulate these processes.25  Therefore, DNA is a vital “database” of all 
genetic information, and this information must be duplicated during replication every time 
a cell undergoes mitosis.  The central roles played by DNA makes it a very good target 
for low molecular weight ligands that may be able to alter or inhibit these processes due 
to their potential ability to bind to DNA.  To better understand what molecular 
characteristics would be favorable for targeting DNA as a drug receptor, it is important to 
understand the structure of DNA itself. 
 
Figure 1.1. The “Central Dogma of Molecular Biology.” 
 
1.2.2. Structure of B-Form DNA  
 DNA is composed of two phosphodiester-linked nucleotide strands that align in 
an anti-parallel fashion and ultimately form a double helical structure.23  The interior of 
the DNA helix contains stacked base pairs of purines and pyrimidines that are attached 
to the C1′ of the ribose ring via an N-glycosidic bond and interact with each other via 
hydrogen bonds to form Watson-Crick base pairs (Figure 1.2).  Watson-Crick base pairs 
are composed of a purine (adenine or guanine) and a pyrimidine (thymine or cytosine) 
nucleobase.  More specifically, adenine (A) and thymine (T) are hydrogen-bonding 
partners and cytosine (C) and guanine (G) are hydrogen-bonding partners.  A•T pairs 
are formed via two hydrogen bonds, and G•C pairs are formed via three hydrogen bonds 
(Figure 1.3).  These base pairs are isostructural and can replace one another without 
altering the position of the C1′ atom in the sugar-phosphate backbone.24  Also, Watson-
Crick base pairs can be exchanged without disturbing the double helix (change G•C to 
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C•G or A•T to T•A).  As a consequence of helix formation, the bases occupy the core of 
the helix and the sugar-phosphate chains are coiled about its periphery, thereby 
minimizing the repulsions between charged phosphate groups.  The negative charges of 
each phosphodiester bond result in an anionic polymer backbone.  Thus, electrostatics 
play a major role in the binding of low molecular weight ligands and proteins to DNA. 
 
 
Figure 1.2. Primary structure of DNA. 
 
 
  
Figure 1.3. A•T and G•C Watson-Crick base pairs of DNA. 
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 DNA can adopt three major polymorphs: A-form, B-form, and Z-form (Figure 
1.4)25, of which B-form is the most relevant under physiological conditions (pH 7.2, 0.15 
M NaCl).  B-DNA is a right-handed double helix with approximately 10 nucleotides per 
helical turn.  The π-π stacked nucleobases are nearly perpendicular to the helix axis of 
B-DNA.  In comparison, A-DNA is wider than B-DNA and has base pairs inclined to its 
helix axis instead of perpendicular to it; and Z-DNA is a left-handed helix whose repeat 
units are dinucleotides that lead to a “zigzag” backbone.25  The conformation adopted by 
DNA depends upon the hydration level, DNA nucleotide sequence, and chemical 
modification of the bases.  Overall, DNA can exhibit several different conformations in 
different sequence segments.25,26  
 
Figure 1.4. Structures of A, B, and Z-DNA (left to right).25 
 
 The double helix structure of DNA leads to two asymmetrical exterior grooves 
that run between the anionic backbones and constitute opposite sides of each base pair 
plane.  In B-DNA, there is a wide and deep major groove and a narrow and deep minor 
groove (Figure 1.5) that results from the asymmetric connection of the Watson-Crick 
base pairs to the phosphate backbone.27  The edges of the stacked base pairs constitute 
the floor of the grooves and present different hydrogen-bond acceptors and donors to 
ligands.  In general, the major groove is the preferred recognition site for proteins 
because its width accommodates bulkier ligands and makes the groove floor accessible 
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for the binding functionalities of a protein to interact with the stacked edges of the base 
pairs.  The edges of A•T and G•C base pairs provide three possible hydrogen-bonding 
sites within the DNA major groove.  There are two hydrogen-bond acceptors (adenine-
N7 and thymine-O4) and one hydrogen-bond donor (adenine-N6) for A•T base pairs, 
and there are two hydrogen-bond acceptors (guanine-N7 and guanine-O4) and one 
hydrogen-bond donor (cytosine-N4) for G•C base pairs.28  Bulky proteins generally 
identify bases in the major groove for their site-specific binding, often using α-helical 
structural elements in their binding and DNA recognition. 
 
 
Figure 1.5. Structure of the B-form DNA double helix.25 
 
The narrower minor groove is most often the target for small molecules as 
opposed to bulkier proteins.  Small molecules can fit snuggly into the minor groove, 
which is narrower in regions of high A•T content (6 Å), than regions of high G•C content 
(12 Å), allowing for increased surface contact and enhanced binding affinity.  There are, 
however, fewer functionalities for nucleobase recognition in comparison to the major 
groove: G•C base pairs contain only three accessible hydrogen-bonding sites in the 
minor groove and A•T base pairs contain two hydrogen-bond acceptors (adenine-N3 and 
thymine-O2).28  X-ray studies have shown that the exocyclic N2 amino group of guanine 
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is often a hydrogen-bond donor group.29  However, this same amino group also appears 
to disrupt the association of DNA minor groove binders in G/C-rich regions by protruding 
from the floor of the groove, preventing a close association that would otherwise occur in 
deeper A/T-rich regions.  Conceptually, the three sites in G•C base pairs would compare 
favorably to the two of A•T base pairs, but studies have demonstrated that many binders 
prefer A•T sites.  This suggests that hydrogen bonding is not the sole determinant for 
sequence recognition within the DNA minor groove.  It is likely that electrostatic potential 
is of great importance for minor groove recognition as a series of A•T base pairs has a 
greater negative electrostatic potential at the floor of the groove than that of G•C base 
pairs.7  The more negative electrostatic potential of A•T base pairs is likely the reason 
positively charged ligands prefer A/T-rich regions to G/C-rich regions.   
Much effort has been expended towards understanding the structure of DNA and 
its potential drug binding sites.  It has been established that ligand-DNA binding 
commonly occurs through a combination of electrostatics, van der Waals forces, and 
hydrogen bonding.  The negatively charged phosphodiester backbone forms complexes 
with low molecular weight ligands with positive charges through electrostatic 
interactions; the formation of the Watson-Crick base pairs results in the presence of 
hydrophobic features along the walls of the groove.  Knowledge of the numerous binding 
sites in DNA and the methods known DNA binders use to bind to DNA aids our attempts 
to develop new molecules with increased binding affinity and specificity.  This thesis will 
focus on utilizing low molecular weight ligand-DNA interactions of the minor groove in 
our design of amino acid-benzimidazole-amidine conjugates as possible DNA minor 
groove binding ligands. 
 
1.3. DNA Ligand Binding Modes 
 There are several DNA-ligand binding modes, including (1) exterior surface 
binding which is mainly electrostatically driven, (2) intercalation, and (3) groove binding 
to either the major or minor groove.  DNA intercalators are typically positively-charged, 
rigid, planar aromatic compounds that insert between two adjacent stacked Watson-
Crick base pairs (Figure 1.6)30 resulting in the DNA and binder undergoing 
conformational changes upon their interaction, often leading to distortion of the DNA 
helix in DNA-ligand complexes.31  In DNA, intercalation is a two-stage process including 
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(1) an initial diffusion-controlled association of the intercalator with the exterior of the 
helix followed by (2) a slower insertion of the intercalator between stacked base pairs.  
When intercalation occurs, the flanking base pairs must separate approximately 0.3 nm, 
causing structural changes in the DNA which can lead to inhibition of transcription and 
replication.  Intercalators can also resemble another base pair and cause enzymes to 
make errors in transcription, resulting in the addition of an extra base that alters the 
triplet code generating an altered sequence.  Therefore, many intercalators are powerful 
mutagens and in some cases can be used in chemotherapeutic treatments to inhibit 
cancer cell replication.12,32,33  Ethidium bromide and thiazole orange (Figure 1.7) are two 
common intercalating dyes that display enhanced fluorescence upon DNA binding.  
These agents are also important dyes for measuring DNA binding affinity of ligands in 
fluorescent intercalator displacement (FID) experiments34,35 or to visualize DNA 
fragments in agarose gel electrophoresis.36,37  
 
Figure 1.6. Ethidium bromide intercalated between two DNA base pairs. 
 
 
 
Figure 1.7. Structures of ethidium bromide and thiazole orange. 
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There are many factors involved in DNA minor groove binding, thus only the 
major influences will be discussed.  The natural products netropsin and distamycin have 
played an integral role in understanding these mechanisms of small molecule-DNA 
minor groove recognition.  An early crystal structure of netropsin bound to DNA revealed 
that minor groove binding occurs when netropsin aligns along the groove cleft of B-DNA 
and forms hydrogen bonds with the floor of the groove.38  Overall, small molecule DNA 
recognition occurs through a combination of electrostatic interactions with the 
phosphodiester backbone, hydrogen bonding to the nucleobases, van der Waals contact 
with the walls of the groove, hydrophobic interactions, and steric hindrance to influence 
the mode of ligand binding to DNA.39  The sugar-phosphate backbone of DNA, which is 
negatively charged, is attractive to positively charged ligands which results in an 
increase of ligand concentration near DNA from bulk solution.  As stated earlier, A•T 
regions of B-DNA have greater negative potential than those of G•C regions due to the 
presence of electron rich thymine-O2 and adenine-N3 as well as the narrowed groove 
width, making A•T regions targets for positively charged ligands.  Therefore, minor 
groove binding ligands typically have at least one positively charged group to enhance 
its A•T site selectivity as well as binding affinity. 
 The width, structurally, of the groove around the helix can also play a part in the 
minor groove binding of ligands to DNA.  In regions of high A•T content, the groove is 
narrower, whereas regions of high G•C content have a wider groove due, as noted 
earlier, to the exocyclic group of guanine.  An x-ray structure of netropsin bound to DNA 
suggest the exocyclic group protrudes from the floor of the minor groove and causes 
steric hindrance that interferes with binding in regions of high G•C content.40  Many 
minor groove binders are elongated structures that contain multiple hydrogen-bonding 
functionalities, therefore the narrower groove in A/T-rich regions contributes to the 
hydrophobic contacts made with the surfaces of small molecules.41  The narrower 
groove in A/T-rich regions aids in aligning small molecules so that hydrogen-bonding 
groups are directly exposed to the floor of the groove, whereas the wider groove in G/C-
rich regions does not provide the tight fit to aid in binding by planar ligands.   
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1.4. Examples of DNA Minor Groove Binding Ligands 
  
1.4.1. Netropsin 
Netropsin, a natural product observed to bind to the minor groove of B-DNA, is a 
polyamide that has been shown to display in vitro antiviral activity, but is not 
administered clinically due to its high toxicity.42  Netropsin (Figure 1.8) consists of two 
carboxamide-linked N-methylpyrrole units with two positively-charged terminal groups, a 
guanidinium and an amidinium that aid in binding to the DNA minor groove.43,44   
 
 
Figure 1.8. Structure of netropsin. 
 
Crystal structures of netropsin bound to A/T-rich regions of DNA have shown that 
binding occurs when netropsin aligns in the minor groove of DNA and forms hydrogen 
bonds within the groove (Figure 1.9).10,45-47  When bound to DNA, netropsin adopts a 
crescent shape that nicely complements the curvature of the minor groove for a span of 
four base pairs and there is a combination of non-covalent interactions that further 
contribute to binding; these have been confirmed by NMR and X-ray studies.8,9  The 
positively charged amidinium and guanidinium facilitate delivery of the ligand to the 
minor groove.  Upon docking, hydrophobic contacts between the ligand and the minor 
groove walls leads to an affinity-enhancing interaction and hydrogen bonding occurs 
between the amide hydrogens and the adenine-N3 or thymine-O2.  An illustration of the 
hydrogen bonds formed between netropsin and the minor groove is presented in Figure 
1.10.48  The roles of the positively charged ends of the ligand as well as the hydrogen 
bonding that occurs in the groove are both ideas that are central to the development of 
our amino acid-benzimidazole-amidine conjugates. 
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Figure 1.9. Netropsin bound to the minor groove of 5′-AATT DNA.10 
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Figure 1.10. Hydrogen bonding observed between netropsin and the AATT 
oligonucleotide.48 
 
It has been established that netropsin prefers to bind to A/T-rich regions of the 
DNA minor groove, and FID studies have given further details about the preferred 
binding sites of netropsin to DNA (Figure 1.11).49  The FID analysis of netropsin yielded 
merged-bar histograms of the rank-ordered 136 hairpin, four-base pair library with a 
steep plot curvature associated with sequences that provide preferred binding sites as 
well as the expected horizontal and vertical displacement of the FID profile with 
increased netropsin concentration.49  As expected, the A/T-only sequences were the 
preferred binding sites and 9 of 10 possible sequences were found within the first 11 
sequences in the rank-order, further underscoring the A/T-preference of netropsin. 
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Figure 1.11. Merged-bar FID histogram of netropsin at 0.75 and 1.5 μM.49 
 
1.4.2. Distamycin 
Another example of a polyamide that binds preferentially to A/T-rich regions of 
the DNA minor groove is distamycin (Figure 1.12).9  The structure of distamycin includes 
pyrrole groups linked by amide bonds with an N-terminal formyl group and a positively 
charged amidinium.  Distamycin binds to DNA very similar to netropsin.  Distamycin 
requires four A/T base pairs as established by NMR and X-ray studies.49,50  DNA-
distamycin binding at asymmetric sites is directional with the N-terminal formyl group 
pointing toward the 5' end of the A/T-rich strand.  Along with 1:1 binding, two distamycin 
ligands can bind simultaneously to sites with at least five A•T base pairs.  In these 2:1 
complexes (Figure 1.13), two distamycin ligands are stacked side by side, and the 
positively charged end groups point in opposite directions.51  The formyl group of each 
ligand lies at the 5' end of the adjacent strand.  To accommodate the second ligand in 
this 2:1 motif, the minor groove must be widened by approximately 3.5 Å relative to the 
1:1 complex.  The 2:1 motif spans five base pairs, and in six-base-pair sites, 2:1 
complexes rapidly slide between overlapping five-base-pair sites.52-54  The relative 
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binding constants of the ligands and the preference for the 2:1 over the 1:1 mode varies 
significantly with the DNA sequence.   
 
 
Figure 1.12. Structure of distamycin. 
 
 
 
Figure 1.13. Structures of polyamides bound to DNA: (A) 2:1 motif, (B) 1:1 motif.51 
 
Similar to netropsin, FID studies of distamycin show an expected increased 
affinity for regions rich in A•T bases in a 512-member library containing all possible 5 
base pair combinations of nucleobases (Figure 1.14).55  The FID histogram showed the 
presence of all but two five-bp A/T-sites in the top 45 sequences and all but two four-bp 
A/T-sites in the top 151 sequences.  The top 50 sequences were comprised of 14 (of 16 
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possible, 88%) five-bp A/T-sites, 15 (of 32 possible, 47%) four-bp A/T-sites, 10 (of 80 
possible, 13%) three bp A/T-sites, and 11 (of 176 possible, 6%) two bp A/T-sites, 
illustrating a preference for sites containing four or five A•T base pairs over sites with two 
or three base pairs.55  These findings for distamycin, like those of netropsin, also point to 
the importance of having a positively charged moiety and many different hydrogen-
bonding groups present in A•T selective minor groove binders. 
 
 
Figure 1.14. Merged-bar FID histogram of distamycin at 2.0 μM: (A) all 512 
oligonucleotide sequences, (B) top 50 sequences showing highest affinity.55 
 
1.4.3. Synthetic Polyamides 
The natural products netropsin and distamycin and their A•T site selectivities 
have inspired the development of synthetic minor groove binders.  It was proposed early 
on that netropsin and distamycin-like molecules could be developed to specifically 
recognize the guanidine exocyclic amino group through hydrogen bonding, thus 
expanding the DNA recognition of these agents to G•C containing regions.56,57  Many 
such so-called lexitropsins, where methylimidazole rings are substituted for 
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methylpyrrole rings (Figure 1.15) were developed to introduce a guanidine-specific 
hydrogen-bond acceptor.58-64  Unfortunately, these lexitropsins did not become G•C 
specific despite losing their preference for A•T sites.  This is likely because there is still 
considerable A/T-site recognition inherent to the structure due to amide hydrogens and 
the positively charged terminal moiety as well as the overall shape of the ligand.  
 
 
Figure 1.15. Lexitropsin 2-imidazole-distamycin with arrows indicating hydrogen 
accepting and donating groups in red and blue, respecitively. 
 
Building upon the lexitropsins, a more recent polyamide design arose from the 
discovery of the 2:1 binding mode displayed by distamycin within the minor groove.10  It 
was shown by NMR studies that two distamycin molecules could align in an antiparallel 
orientation in A/T-rich regions of the DNA minor groove,65 and, similarily, two synthetic 
polyamides can fit side by side and form hydrogen bonds within the minor groove.  This 
antiparallel side-by-side arrangement aligned the five-membered heterocycles against 
each other, allowing contact within the walls of the minor groove.  Crystal structures of 
the DNA-polyamide complexes have shown that the spacing of polyamide rings matches 
the spacing of DNA base pairs.66-68  Importantly, given this arrangement, the four 
Watson-Crick base pairs can be differentiated in the minor groove by the specific 
positions of their hydrogen-bond donors and acceptors.69  A•T can be distinguished from 
T•A by utilizing the lone pairs of electrons on the thymine-O2.  Therefore, side-by-side 
pairing allows for a specific pattern of hydrogen bonding. 
Employing the above, Dervan et al. have shown that polyamides are amenable to 
synthetic manipulation, allowing their physical properties and minor groove interactions 
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to be controlled.  Moreover, over two decades of work has gone into the development of 
hairpin polyamides and what has become known as the “Pairing Code.”10  This has led 
to a new model of sequence-specific recognition in the DNA minor groove.  Polyamides 
are comprised of combinations of methylimidazole (Im), methylpyrrole (Py), and methyl-
3-hydroxypyrrole (Hp) units to form molecules that bind to the minor groove as 
antiparallel dimers.  Covalently linking the amino- and carboxyl-termini of two antiparallel 
dimers with an aliphatic γ-aminobutyric acid resulted in hairpin polyamides that could 
recognize all combinations of base pairs as illustrated for one sequence in Figure 
1.16.10,65  
 
 
Figure 1.16. Pairing code illustrating the contacts of polyamides with minor groove.  
Note, the structure of the Hp extends a hydrogen deep into the groove to interact with 
sterically hindered thymine-O2 lone pair.65 
 
Although the Pairing Code has aided the successful targeting of many DNA 
sequences, there are many more sequences that are difficult to target with high affinity 
and specificity.  In addition, the Hp residue noted above degrades over time in the 
presence of acid or free radicals.  Therefore a more stable thymine-selective moiety is 
desired.  Because of this, research in the area of minor groove binding polyamides has 
been directed toward developing heterocycles with improved stability and recognition 
capability.10  Phenyl-benzimidazoles exhibit several of these desired qualities due to 
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their slightly different curvature and ability to recognize DNA through two sets of 
hydrogen-bond donating groups.70  This curvature, as well as the possible hydrogen 
bonding that can occur in the minor groove with the benzimidazole are key to including 
benzimidazoles in our design of minor groove binding ligands. 
 
1.5. Benzimidazole-Based DNA Minor Groove Binders 
 Phenyl-benzimidazole ring systems represent a structural framework that is 
amenable to functionalization and imparts a curvature that complements the DNA minor 
groove.  Benzimidazole derivatives have been incorporated into the backbones of 
polyamides in a manner that preserves hydrogen bonding contact with the minor 
groove.71  Indeed, (1) the classic minor groove-binding Hoechst dyes are composed of 
benzimidazole units and (2) hydroxybenzimidazole (Hz) and imidazopyridine (Ip) rings 
have been included in polyamides without an amide linker between the rings.  It has 
been shown that Py-Hz and Py-Ip pairs are functionally identical to the five-membered 
ring pairs Py-Hp and Py-Im.72  The Py-Hz pair has been shown to distinguish T/A from 
A/T base pairs while the Py-Ip pair has been shown to  distinguish G/C from C/G base 
pairs.  The benzimidazole containing polyamides have proven to be more chemically 
stable and have been incorporated into effective minor groove binding DNA ligands. 
 
1.5.1. Hoechst 33258 
 Hoechst 33258 (Figure 1.17) is a bis-benzimidazole comprised of two linked 
benzimidazole groups with a phenol and methylpiperazine at either end.  Hoechst 33258 
has been employed as a chromosomal stain73 and a fluorescence indicator74 due to its 
ability to be excited by ultraviolet light at ~350 nm and to exhibit enhanced fluorescence 
upon binding to DNA.  DNA footprinting and biophysical studies have shown Hoechst 
33258 binds selectively to A•T sequences.74  Hoechst has been shown to exhibit 
antitumor activity and was in phase I/II clincal trials against pancreatic carcinomas 
before being abandoned due to its toxicity.75,76  
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Figure 1.17. Structure of Hoechst 33258. 
 
 Hoechst 33258 and its interactions with DNA have been extensively studied 
using a number of techniques including NMR and X-ray crystallographic analysis.72,77-79  
Similar to netropsin and distamycin, Hoechst 33258 binds preferentially to A/T-rich 
regions of the DNA minor groove.80  These results are confirmed by FID analysis (Figure 
1.18).55  The FID histogram showed the presence of 16 (of 16 possible, 100%) five-bp 
A/T-sites and 19 (of 32 possible, 59%) four-bp A/T-sites within the top 50 sequences 
with the top 20 sequences being exclusively four- or five-bp A/T-sites.55  When Hoechst 
33258 is bound to A/T-rich DNA, hydrogen bonds form between the benzimidazole 
nitrogen atoms and the minor groove of DNA when the benzimidazole donor can contact 
the thymine-O2 or adenine-N3 atoms in a conformation similar to that of netropsin.81  
The bulky N-methylpiperazine ring of Hoechst is usually located in a wider G•C portion of 
the minor groove flanking A/T-rich sequences without participating in hydrogen bonding. 
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Figure 1.18. Merged-bar FID histogram of Hoechst 33258 at 2.0 μM: (A) all 512 
oligonucleotide sequences, (B) top 50 sequences showing highest affinity.55 
 
The effect of amino acids on the binding affinity of Hoechst 33258 was explored 
by incorporating the full structure of Hoechst 33258 into peptides and testing their 
binding affinity and site selectivity.82  The results of simple Hoechst 33258 conjugates 
(Figure 1.19) show nearly the same binding preference for A/T-rich regions of DNA as 
that for the parent Hoechst 33258 while increasing up to 60 times the binding affinity for 
the peptide-Hoechst 33258 conjugate.82  This shows the benzimidazole moiety is 
important for DNA minor groove recognition and that conjugation with amino acids can 
increase the binding affinity without altering the sequence preference of the parent 
structure, showing us that amino acid-benzimidazole-amidine conjugates can also be 
strong DNA minor groove binders.  As will be described, we incorporated amino acids 
into our benzimidazoles as has been done with some Hoechst systems, although we 
elected to use fewer amino acids and only included a single benzimidazole moiety in our 
design compared to the di-benzimidazole-amino acid Hoechst systems to keep our 
molecules small and compact while increasing their binding affinity over non-amino acid 
containing benzimidazole-amidine systems. 
21 
 
 
 
Figure 1.19. Structures of (A) a simple Hoechst 33258 analogue and (B) a Hoechst-
peptide conjugate. 
 
1.5.2. Benzimidazole-Amidine Systems 
 In addition to Hoechst, benzimidazole-amidine systems such as RT29 (Figure 
1.20) and a series of furamidine and related diamidine dication compounds, refered to as 
the DB series (Figure 1.21), provide a favorable and flexible DNA recognition 
element.17,83-87  RT 29 is a benzimidazole diphenyl ether core that is capped by amidine 
groups. FID analysis of RT 29 shows a similar rank order to what has previously been 
reported for netropsin, proving RT 29 to be another A/T-rich minor groove DNA 
binder.17,83  Crystallographic results for the DNA complex with RT29 shows the 
compound undergoes significant conformational changes and incorporates a water 
molecule directly into the complex to allow it to adopt a crescent shape and complete the 
compound-DNA interface.17,83  RT 29 is attractive to the minor groove of A/T-rich regions 
due to the positive charge character of the two cationic amidine groups, and the 
nitrogens also participate in hydrogen bonding with A/T bases.88-90   
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Figure 1.20. Structure of RT 29. 
 
 
 
Figure 1.21. Structures of DB Series Compounds. 
 
Among heterocyclic diamidines, DB293 has been shown to bind to A/T-rich sites 
as a monomer and as a stacked dimer similar to distamycin.91  X-ray crystallographic 
analysis of DB921 bound to an AATT sequence suggests a water molecule is also able 
to complete the curvature of DB921 for minor groove interactions,87 and DB921 binds to 
A/T-rich DNA sequences stronger than the rest of the DB series with a binding constant 
of greater than 108 M-1 under physiological conditions.18  Finally, the prodrug DB75 has 
shown activity against eukaryotic parasitic diseases and is in Phase III clincal trials 
against sleeping sickness.92  Aromatic diamidines have drawn interest due to their 
antimicrobial activity which is believed to be a result of their minor groove binding 
affinity.93  The combination of extra hydrogen bonding from amidines along with that of 
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the benzimidazole make compounds containing these moieties strong targets for the 
development of DNA minor groove binding agents. 
 In summary, we have introduced benzimidazole compounds, benzimidazole-
amidine systems, and benzimidazole-peptide conjugates.  Benzimidazoles are good 
minor groove A/T-rich region binding moieties due to their ability to hydrogen bond with 
the floor of the the minor groove and that their size is not too bulky to be accommodated 
by the minor groove.  The positively charged amidine moiety is drawn to the more 
negatively charged A/T regions of DNA and provides excellent affinity for these regions.  
Peptides conjugated with these moieties can enhance the binding affinity.  Therefore, we 
hypothesize that amino acid-benzimidazole-amidine conjugates should be good DNA 
minor groove binders due to the combination of these advantageous features. 
 
1.6. Plan of Study 
 The subsequent chapters of this thesis will describe a new series of amino acid-
phenyl-benzimidazole-amidine conjugates designed in our laboratory.  These 
compounds consist of a phenyl-benzimidazole-amidine core conjugated to different 
amino acids (Figure 1.22).  The structural basis for the design of minor groove binding 
ligands and key features that are important to minor groove binding ligands include: (1) 
incorporating amino acids to provide structural diversity, (2) positive charges that 
enhance electrostatic interactions, (3) and hydrogen-bonding groups for sequence 
recognition.  By incorporating many key features from different binders as introduced 
here, it was anticipated that a series of selective and high affinity minor groove binding 
agents would emerge.  The phenyl-benzimidazole is a stable and strong binder to A/T-
rich regions of the DNA minor groove; the positively charged amidine group is attracted 
to the negative potential of the DNA minor groove, which is highest in A/T-rich regions; 
and amino acids provide subtle structural diversity to perhaps drive different conjugates 
toward different DNA sites.  The combination of these groups should yield a strong and 
selective binder to A/T-rich regions, and perhaps other sequences, of the DNA minor 
groove. 
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Figure 1.22. Structure of model amino acid-phenyl-benzimidazole-amidine system. 
 
 The focus of this study was to develop the synthesis of the amino acid-
benzimidazole-amidine system that we have designed and to determine their relative 
DNA binding affinities.  All conjugates will be synthesized on solid-phase support and 
their relative binding will be measured with the FID assay.  Conjugates of this form have 
never been explored, and the solid-phase synthesis of benzimidazole-amidine systems 
has not been reported.  Therefore, the synthetic protocol will be useful to supplement 
solid-phase synthesis. 
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CHAPTER 2. DESIGN AND SYNTHESIS OF AMINO ACID-BENZIMIDAZOLE- 
AMIDINE CONJUGATES 
 
2.1. Design of Amino Acid-Benzimidazole-Amidine Conjugates 
Benzimidazoles and their derivatives are powerful antitumor, antifungal, and 
antiviral compounds1-4 that have been employed extensively in the design of DNA minor 
groove targeted compounds.5  The structure of the benzimidazole ring system has been 
shown to be a good design element for recognition of the DNA minor groove due to the 
presence of heteroatoms in the ring that promote hydrogen bonding and, as part of a 
phenyl-benzimidazole, the overall curvature of these systems can closely resemble that 
of the minor groove itself.6-9  Therefore, benzimidazoles provide a building block for 
further structural variability, and they have been shown to exhibit excellent interactions 
with the minor groove of DNA in many systems.10-17  Because of these qualities, 
benzimidazoles were included in the design of our DNA minor groove targeted 
compounds. 
In addition to the benzimidazole moiety, amidines have been shown to be an 
important pharmacophore in medicinal chemistry.  More specifically, aromatic amidines 
have been shown to function as arginine side-chain mimetics due to their favorable 
spatial and cationic properties.18,19  Many of the previously mentioned DNA minor groove 
binders, such as netropsin, distamycin, RT 29, and the DB series, include amidine 
moieties. An amidine contributes a positive charge which aids in recognition of the minor 
groove, more specifically, A/T-rich sites that have a greater negative electrostatic 
potential.11,19-25  These desirable qualities led to the inclusion of the amidine moiety in 
our design of DNA minor groove binding targets. 
Amino acids were also included in our design to provide structural diversity to the 
basic phenyl-benzimidazole structure.  The differing side chains of each amino acid 
provide subtle structural differences to the overall molecule which may lead to the 
targeting of different DNA sequences.  Individual amino acids or small chains of amino 
acids should be compact enough to fit into the DNA minor groove, and these will contain 
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multiple amide bonds similar to the structures of netropsin, distamycin, and the 
lexitropsins11,19-21,26-29  Because of these qualities, we have designed benzimidazole-
amidine systems that include a single amino acid and systems that include two amino 
acids.  The basic structures of our resin bound benzimidazole-amidine systems are 
shown in Figure 2.1. 
 
 
 
Figure 2.1. Resin-bound benzimidazole amidine systems: (A) single amino acid- and 
(B) di-amino acid-benzimidazole-amidine conjugates where Xaa is any one of 20 
naturally occurring amino acids (except Trp, Ser, Cys, or His for structure A). 
 
2.2. Synthesis – General Considerations 
Solid-phase synthetic methods for the generation of amino acid conjugates have 
become increasingly important since the development of solid-phase peptide 
synthesis.30  As such, all of our planned syntheses were carried out via solid-phase 
synthetic protocols because they are amenable to quickly and easily assembling peptide 
bonds as well as their ease of purification.  Numerous solid-phase resins have been 
developed over the years to yield desirable terminal functionalities after product 
cleavage, and a couple of the most commonly used resins in solid-phase chemistry are 
Rink amide resin and Wang resin (Figure 2.2).  Rink amide resin was specifically used to 
build our compounds because upon final cleavage of product from the resin an amide 
terminal group is formed whereas Wang resins result in a terminal carboxylic acid.  In 
our case, the resulting amide termini will not possess a charge under physiological 
conditions and can act as a hydrogen bond donor to potentially aid in the recognition of 
the DNA minor groove.  In contrast, a carboxylic acid would generate a product with a 
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negative charge which would repel the negatively charged DNA phosphodiester 
backbone.  Base-labile Fmoc-group protected amino acids were coupled to the 
deprotected Rink amide resin through their C-termini via established peptide bond 
forming solid-phase synthetic protocols (Figure 2.3).31-33  Amino acids containing side-
chain protecting groups that can be easily removed during TFA resin cleavage were 
used to avoid extra steps to remove the protecting group.  
 
 
 
Figure 2.2. Structures of Rink amide resin and Wang resin, arrows indicate coupling 
sites. 
 
 
 
 
Figure 2.3. Solid-phase coupling of amino acid to Rink amide resin. 
 
Due to the importance of the amidine group to the recognition of minor groove 
binding agents, we sought to include this moiety into our systems.  Earlier, our group 
had attempted to incorporate amidines into resin-bound benzimidazole structures via the 
Pinner conversion34-37 of a nitrile with an alcohol in gaseous HCl to form an alkyl imidate 
which can then be treated with an amine and the catalytic hydrogenation of an 
amidoxime with palladium on charcoal,25,38-40 but neither of these reactions was 
successful on resin.  However, it has also been shown that SnCl2•2H2O can reduce 
aromatic nitro compounds to amines on solid support.41  To overcome the lack of an 
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efficient method to synthesize an amidine on resin, a milder procedure using 
SnCl2•2H2O (Figure 2.4) to reduce the amidoxime moiety was employed in this new 
work.   
 
 
Figure 2.4. Solid-phase amidoxime reduction. 
 
 As a means to monitor coupling efficiency during the course of the synthesis, the 
Kaiser test was employed to quickly and efficiently check for the presence of amines to 
avoid incomplete peptide chain synthesis.42   Typically, a few resin beads are removed 
from the reaction mixture, washed, and dried, then placed in a test tube.  2-3 drops of (1) 
500 mg ninhydrin dissolved in 10 mL EtOH, (2) 80 g phenol in 20 mL EtOH, and (3) 2 
mL 0.001 M KCN diluted to 100 mL in pyridine are added to the resin and placed in a 
heating block at 100 °C for 5 minutes.  A negative test for free amine yields no color 
change to the resin, whereas a positive test yields a deep purple color change to the 
resin.  The Kaiser test was used extensively throughout the synthesis of our amino acid-
benzimidazole-amidine conjugates to check the progress of each coupling. 
 
2.2.1. Synthesis of 3,4-Diaminobenzamidoxime 
To provide us with a group that could be reduced to form an amidine moiety on 
resin, we synthesized a benzamidoxime group that can be coupled easily to a free 
aldehyde on resin.  The synthesis of our amidoxime group was not performed on resin, 
but was instead synthesized in solution by heating 3,4-diaminobenzonitrile in the 
presence of 10 equivalents of 50% aqueous hydroxylamine for 5 hours (Figure 2.5).  
This reaction was carried out initially at room temperature overnight before optimization 
determined that performing the reaction under reflux provided much higher yield (up to 
90%) than allowing the reaction to stir overnight without heating.  Product was 
characterized by LC/MS and 1H NMR (Figure 2.6 & Table 2.1).  
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Figure 2.5. Synthesis of 3,4-diaminobenzamidoxime (1). 
 
 
Figure 2.6. 1H NMR of purified 3,4-diaminobenzamidoxime (1) in DMSO-d6. 
 
2.2.2. Benzimidazole-Amidines Lacking Amino Acid Diversity 
The benzimidazole-amidine system was initially developed without including 
amino acids.  These model systems were studied to optimize the synthesis of the 
benzimidazole-amidine core, more specifically to improve the problematic synthesis of 
the amidine.  Past attempts to reduce the amidoxime group to an amidine yielded no or 
very little desired product upon cleavage, thus the reaction conditions of this step 
required optimization to produce desirable products.  These attempts will be touched 
upon in the following section.  
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Initially, we explored the synthesis of phenyl-benzimidazole-amidines on resin 
(Figure 2.7).  First, 4-carboxybenzaldehyde was coupled to deprotected Rink amide 
resin under conditions similar to those used in the coupling of amino acids to the resin.  
The Fmoc protecting group of commercial Rink amide resin was removed by allowing 
the resin to shake for 30 min at room temperature in a 1:4 (v/v) mixture of piperidine and 
DMF.  Increased piperidine concentrations were tried but they did not appear to shorten 
reaction time and shorter reaction times at 20% piperidine did not always yield complete 
deprotection.  The resin was washed with DMF, methanol, DCM, and diethyl ether and 
the presence of a terminal amino group was confirmed using a Kaiser test.   
 
 
 
Figure 2.7. Solid-phase synthesis of phenyl-benzimidazole-amidine. 
 
Upon deprotection of the resin, 5 equivalents of 4-carboxybenzaldehyde, 1-
hydroxybenzotriazole (HOBt), and diisopropylcarbodiimide (DIC) were added, based 
upon 0.25 g of resin at 0.66 mmol/g resin loading.  To allow the formation of an amide 
bond between the free amine of the resin and the carboxylic acid group of the 
carboxybenzaldehyde, the reaction was shaken at room temperature for 1.5 hours and 
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monitored via Kaiser test.  When purple resin beads were present, indicating an 
incomplete coupling, a second coupling of five equivalents of 4-carboxybenzaldehyde 
was performed.  Initially, the amount of 4-carboxybenzaldehyde added was increased up 
to 10 times excess in an attempt to complete the coupling in the initial 1.5 hours, or 
shorter if possible, but there was no discernible difference observed versus using five 
equivalents.  Reaction times up to 5 hours were also attempted, but the coupling was 
still incomplete.  Finally, it was decided that doing a double coupling with 1.5 hour 
reaction times was the most efficient way to proceed with this step of the reaction.  The 
resin was again washed with DMF, methanol, DCM, and diethyl ether and the completed 
coupling of the carboxybenzaldehyde to the resin was confirmed by Kaiser test. 
Next, the benzimidazole ring was formed via the condensation of the aldehyde 
(from 4-carboxybenzaldehyde) with 3,4-diaminobenzamidoxime.  Ten equivalents of the 
amidoxime-containing diaminobenzene 1 was allowed to react with the resin-linked 
aldehyde for five hours at 60 °C.  In an attempt to conserve the diaminobenzene, 
syntheses using five equivalents were attempted but did not yield complete coupling in 
five hours and required overnight reactions to reach completion.  Also, differing reaction 
times were attempted with shorter times showing incomplete coupling via LC/MS 
(mixture of product and starting material) and longer reaction times showing no 
difference to five hours.  The reaction was also conducted at room temperature but 
would typically take up to 24 hours to show complete coupling.  After the formation of the 
benzimidazole was complete, resins were washed with DMF, methanol, DCM, and 
diethyl ether and the amidoxime group was reduced to the desired amidine moiety.   
The reduction of resin-bound amidoxime to resin-bound amidine proved to be the 
most difficult reaction leading to final product, but was eventually achieved by adding 15 
equivalents of 1 M SnCl2•2H2O in DMF to the resin-bound benzimidazole amidoxime and 
allowing the reaction to proceed at 70 °C for over 40 hours.  To increase the reaction 
yield, a new aliquot of the SnCl2 solution was added to the reaction mixture every 4 
hours.  Initially performing the reaction with only one aliquot of 1 M SnCl2•2H2O led to 
the reaction mixture thickening to the point that stirring would no longer occur and upon 
cleavage, very little or no desired product was seen.  Increasing the concentration and/or 
volume of 1 M SnCl2•2H2O did not alleviate this problem and usually resulted in less 
than 25% yield.  Eventually, additional aliquots of 1 M SnCl2•2H2O were added to the 
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reaction vessel and it was determined that adding a new aliquot every four hours 
throughout the day would prevent the reaction mixture from thickening and yielded 
desired product upon cleavage.  Shorter durations of the entire reaction were attempted 
but at 24 hours there was still a large amount of unreacted amidoxime present, so 40 
hours remained the overall length of reaction time.   
Upon the final amidine formation, the phenyl-benzimidazole-amidine was cleaved 
from the resin with a 1:1 solution of TFA:DCM.  The TFA and DCM were evaporated 
under a flow of nitrogen gas and the resulting residue was dissolved in methanol and 
passed through silica then concentrated leading to a 76% yield.  Product was 
characterized by LC/MS and 1H NMR (Figure 2.8 & Table 2.2).  
 
Figure 2.8. 1H NMR of model-benzimidazole-amidine (2) in DMSO-d6. 
 
2.2.3. Amino Acid-Benzimidazole-Amidine Conjugates 
Having confirmed the ability to synthesize phenyl-benzimidazole-amidines on 
resin in good yield, we proceeded to synthesize amino acid-containing benzimidazole-
amidines.  Two classes of amino acid-benzimidazole-amidines were synthesized: (1) 
containing only a single amino acid (Xaa) and (2) a dipeptide containing an amino acid 
linked via a glycine to the benzimidazole-amidine portion (Xaa-Gly).  The glycine residue 
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was added to provide space between the benzimidazole-amidine portion and the varied 
amino acid. 
 
2.2.3.1. Single Amino Acid-Benzimidazole-Amidine Conjugates 
The syntheses of these conjugates followed the same route described previously 
with the addition of amino acid couplings directly to Rink amide resin preceding the 
coupling of 4-carboxybenzaldehyde (Figure 2.9).  Once resin deprotection was 
confirmed via Kaiser test, five equivalents of the desired amino acid, based upon 0.25 g 
of resin at 0.66 mmol/g resin loading was shaken at room temperature for 1.5 hours.  
Reaction times and reagent concentrations that were tested with 4-
carboxybenzaldehyde were also used with the amino acids but it was also seen that 
higher concentrations did not make the reaction proceed faster.  After washing the resin, 
a Kaiser test was performed to verify the coupling of the amino acid to the resin.  If free 
amine was present, a second coupling of five equivalents of amino acid was performed 
for another 1.5 hours.  Generally, amino acids with side chains that contained protecting 
groups (Trp, Ser, Thr, Asn, Gln, Tyr, Cys, Lys, Arg, His, Asp, and Glu) required a double 
coupling, whereas amino acids with no protecting groups (Gly, Ala, Val, Leu, Ile, Met, 
Pro, and Phe) on their side chains did not require a double coupling.  Once the Kaiser 
test was negative for free amine, the resin-bound amino acid was liberated of its 
protecting Fmoc group via shaking in 20% piperidine, 80% DMF for 30 minutes.  Once 
deprotection was confirmed via Kaiser test, 4-carboxybenzaldehyde was coupled to the 
resin and the benzimidazole and amidine moieties were formed as previously described.  
After cleavage from resin, the Xaa-benzimidazole-amidines were characterized via 
LC/MS and 1H NMR.  Isolated, lyophilized product yields and LC/MS results are reported 
in Table 2.3. A sample 1H NMR of glycine-benzimidazole-amidine is shown in Figure 
2.10 and Table 2.4. 
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Figure 2.9. Solid-phase synthesis of single amino acid-benzimidazole-amidine 
conjugates. 
 
Table 2.1.  Mono-amino acid-benzimidazole-amidine conjugate m/z and yields. 
 
Compound R [M+H]+ m/z Yield Compound R [M+H]+ m/z Yield 
3 Gly 337.3 88% 11 Thr 381.4 77% 
4 Ala 351.4 74% 12 Asn 394.3 79% 
5 Val 379.3 81% 13 Gln 408.5 73% 
6 Leu 393.2 76% 14 Tyr 443.5 61% 
7 Ile 393.2 73% 15 Lys 408.5 64% 
8 Met 411.5 73% 16 Arg 436.5 58% 
9 Pro 377.5 79% 17 Asp 395.1 78% 
10 Phe 427.4 64% 18 Glu 409.4 72% 
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Figure 2.10. Example 1H NMR of glycine-benzimidazole-amidine (3) in DMSO-d6. 
 
2.2.3.2. Dipeptide-Benzimidazole-Amidine Conjugates 
The second series of amino acid-containing benzimidazole-amidine conjugates 
were synthesized following the same technique as the single amino acid-containing 
series.  After the initial resin coupling of one of the twenty naturally occurring amino 
acids, a glycine residue was coupled to the resin-bound amino acid, resulting in a 
dipeptide of the sequence Xaa-Gly.  Following the formation of the dipeptide, 4-
carboxybenzaldehyde was coupled to glycine and the formation of the benzimidazole 
and amidine groups was completed.  After cleavage from resin, the Xaa-Gly-
benzimidazole-amidines were characterized via LC/MS and 1H NMR.  Isolated, 
lyophilized product yields and LC/MS results are reported in Table 2.5.  A sample 1H 
NMR of glycine-glycine-benzimidazole-amidine is shown in Figure 2.11 and Table 2.6. 
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Table 2.2. Di-amino acid-benzimidazole-amidine conjugate m/z and yields. 
 
Compound R [M+H]+ m/z Yield Compound R [M+H]+ m/z Yield 
19 Gly 394.3 93% 29 Thr 438.2 89% 
20 Ala 408.2 82% 30 Asn 451.3 69% 
21 Val 436.3 87% 31 Gln 465.2 73% 
22 Leu 450.2 85% 32 Tyr 500.3 65% 
23 Ile 450.4 91% 33 Cys 440.1 44% 
24 Met 468.2 90% 34 Lys 465.2 94% 
25 Pro 434.3 91% 35 Arg 493.3 78% 
26 Phe 484.3 77% 36 His 474.4 61% 
27 Trp 523.3 74% 37 Asp 452.1 85% 
28 Ser 424.3 59% 38 Glu 466.3 71% 
 
 
 
Figure 2.11. Example 1H NMR of glycine-glycine-benzimidazole-amidine (19) in 
DMSO-d6. 
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2.3. Summary 
A new protocol for synthesizing amino acid-benzimidazole-amidine conjugates 
via solid-phase chemistry was developed.  Sixteen single amino acid-containing phenyl-
benzimidazole-amidine conjugates and 20 dipeptide phenyl-benzimidazole-amidine 
conjugates were synthesized using this method.  Despite numerous attempts, 
tryptophan-, serine-, cysteine-, and histidine-containing single amino acid conjugates 
could not be successfully synthesized.  The likely cause for failure in the synthesis of 
these amino acid conjugates occurred during the reduction step.  All of the Kaiser tests 
throughout the synthesis of these conjugates showed the couplings were going to 
completion as expected, and LC/MS of several intermediate products showed the 
desired masses were present and confirmed that the amino acid, aldehyde, and 
diaminobenzene-amidoxime couplings went to completion.  There was no sign of failed 
coupling until cleavage after the reduction.  Also, the quality of the amino acids should 
not be of concern as the same sources were used to synthesize the dipeptides without 
issue.  It is possible that complex side chains were not stable to the reduction conditions 
without another amino acid stabilizing them or that steric hindrance prevented the 
reduction from proceeding. 
The most difficult aspect of the synthesis was the formation of the amidine group.  
The Pinner synthesis and the catalytic hydrogenation of an amidoxime were not 
successful on resin.  To overcome this, a milder procedure using SnCl2•2H2O to reduce 
the amidoxime moiety was employed.  The synthesis of our amidoxime group was not 
performed on resin, but was instead synthesized in solution by heating 3,4-
diaminobenzonitrile in the presence of 10 equivalents of 50% aqueous hydroxylamine for 
5 hours.  The resulting diamino-amidoxime was coupled to the resin and reduced using 
SnCl2•2H2O.  Although the reaction was time-consuming, this proved to be a much more 
efficient method of forming the desired amidine on resin than previously described 
methods. 
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2.4. Experimental Protocols 
 
2.4.1. Materials 
All chemicals and organic solvents were reagent grade and used directly without 
further purification.  3,4-Diaminobenzonitrile, 4-carboxybenzaldehyde, 50% aqueous 
hydroxylamine, piperidine, 1,4-benzoquinone, tin(II) chloride dihydrate, 
hydroxybenzotriazole, diisopropylcarbodiimide, DMSO-d6, acetonitrile, tetrahydrofuran, 
dichloromethane, methanol, ethanol, diethyl ether, hexanes, dimethylformamide, and 
acetone were purchased from Sigma-Aldrich.  Trifluoroacetic acid was purchased from 
Fisher Scientific.  The amino acids were purchased from Bachem and the Rink amide 
resin was purchased from EMD Millipore.  
 
2.4.2. Instruments 
The NMR used was a 500-MHz Bruker Avance III NMR spectrometer with a 5-
mm broadband probe.  The LC/MS used was an Agilent 1100 series HPLC with a binary 
pump, auto-sampler, and diode array detector with a C18 column of a length-by-width of 
150mm x 4.6mm and 5-micron particle size.  The MS was an Agilent 1946D mass 
spectrometry detector with electrospray ionization. 
 
2.4.3. Syntheses 
 
2.4.3.1. General Synthetic Considerations 
All solid-phase synthetic routes carried out at r.t. were performed in a fritted SPE 
column reservoir (15 mL) fitted with a Teflon stopcock and septa and shaken on a 
mechanical stirrer.  Solid-phase synthetic routes carried out at elevated temperature 
were performed in glass scintillation vials (40 mL) containing a stir bar in a reaction block 
fitted to a hot plate stirrer.  Rink amid resin was distributed to each reaction vessel by 
weight and swelled in 1:1 DCM:DMF for 30 min to 1 h.  Fmoc deprotection of Rink amide 
resin and amino acids was performed by shaking the resin in 1:4 (v/v) piperidine:DMF for 
30 minutes at r.t. Deprotection was monitored via Kaiser test.  A second coupling of 
amino acid or 4-carboxybenzaldehyde was performed after 1.5 hours if the Kaiser test 
revealed free amine was still present.  After completion of each synthetic step, reactants 
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were drained and the resin was washed with DMF (3 x 5 mL), methanol (3 x 5 mL), DCM 
(3 x 5 mL), and diethyl ether (3 x 5 mL) and the solvents were removed by filtration using 
a vacuum system.  All reactions were performed under the presence of nitrogen. 
 
2.4.3.2. General Procedure for Synthesis of Model-BI-(+) 
Deprotected Rink amide resin (0.25 g, 0.66 mmol/g) was treated with 4-
carboxybenzaldehyde (0.8250 mmol, 123.8 mg), HOBt (0.8250 mmol, 111.5 mg), and 
DIC (0.8250 mmol, 104.1 mg) in 15 mL DMF and coupled to the deprotected Rink amide 
resin.  The mixture was shaken on a mechanical stirrer at room temperature for 1.5 h.  
Completion of the coupling was confirmed by the Kaiser test.  3,4-
Diaminobenzamidoxime (1.650 mmol, 274.2 mg) and 1,4-benzoquinone (0.165 mmol, 
17.8 mg) were dissolved in 15 mL DMF and coupled to resin-bound phenylaldehyde in a 
scintillation vial for 5 h at 60 °C using an IKA-Werke mechanical stirrer and heating 
block.  Tin(II) chloride dehydrate (2.475 mmol, 558.5 mg) was dissolved in DMF (2.5 mL) 
and reacted with the resin-linked amidoxime using an IKA-Werke mechanical stirrer and 
heating block at 80 °C over 40 h with new aliquots of the Tin(II) chloride solution being 
added to the reaction mixture every 4 h.  The product was cleaved from the resin via 
shaking in a 1:1 solution of TFA:DCM for 1.5 h.  The resin was removed by filtration and 
rinsed with TFA and the filtrate-containing product was collected in tared vials, then the 
TFA and DCM were evaporated with a stream of nitrogen until only a couple of mL 
remained, which was then precipitated into cold ether.  The resulting solid was dissolved 
in MeOH and initially purified via flushing through a silica column (MeOH) to remove bulk 
impurities and then HPLC purified (A: H2O, 0.1% TFA; B: ACN, 0.1% TFA. Gradient: 0 
min, 80% A; 2 min, 80% A; 20 min, 20% A; 25 min, 0% A; 30 min, 0% A; 32 min, 80% A; 
35 min, 80% A).  Product was confirmed via LC/MS and 1H NMR. 
 
2.4.3.3. General Procedure for Synthesis of Xaa-BI-(+) Conjugates 
Deprotected Rink amide resin (0.25 g, 0.66 mmol/g) was treated with an amino 
acid (0.825 mmol), HOBt (0.8250 mmol, 111.5 mg), and DIC (0.8250 mmol, 104.1 mg) in 
15 mL DMF.  The mixture was shaken on a mechanical stirrer at room temperature for 
1.5 h.  Completion of the coupling was confirmed by the Kaiser test.  4-
Carboxybenzaldehyde (0.8250 mmol, 123.8 mg), HOBt (0.8250 mmol, 111.5 mg), and 
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DIC (0.8250 mmol, 104.1 mg) were dissolved in 15 mL DMF and coupled to deprotected 
resin-bound amino acid on a mechanical stirrer at room temperature for 1.5 h.  
Completion of the coupling was confirmed by the Kaiser test.  3,4-
Diaminobenzamidoxime (1.650 mmol, 274.2 mg) and 1,4-benzoquinone (0.165 mmol, 
17.8 mg) were dissolved in 15 mL DMF and coupled to resin-bound phenylaldehyde in a 
scintillation vial for 5 h at 60 °C using an IKA-Werke mechanical stirrer and heating 
block.  Tin(II) chloride dehydrate (2.475 mmol, 558.5 mg) was dissolved in DMF (2.5 mL) 
and reacted with the resin-linked amidoxime using an IKA-Werke mechanical stirrer and 
heating block at 80 °C over 40 h with new aliquots of the Tin(II) chloride solution being 
added to the reaction mixture every 4 h.  The product was cleaved from the resin via 
shaking in a 1:1 solution of TFA:DCM for 1.5 h.  The resin was removed by filtration and 
rinsed with TFA and the filtrate-containing product was collected in tared vials, then the 
TFA and DCM were evaporated with a stream of nitrogen until only a couple of mL 
remained, which was then precipitated into cold ether.  The resulting solid was dissolved 
in MeOH and initially purified via flushing through a silica column (MeOH) to remove bulk 
impurities and then HPLC purified (A: H2O, 0.1% TFA; B: ACN, 0.1% TFA. Gradient: 0 
min, 80% A; 2 min, 80% A; 20 min, 20% A; 25 min, 0% A; 30 min, 0% A; 32 min, 80% A; 
35 min, 80% A).  Product was confirmed via LC/MS and 1H NMR. 
 
2.4.3.4. General Procedure for Synthesis of Xaa-Gly-BI-(+) Conjugates 
Deprotected Rink amide resin (0.25 g, 0.66 mmol/g) was treated with an amino 
acid (0.825 mmol), HOBt (0.8250 mmol, 111.5 mg), and DIC (0.8250 mmol, 104.1 mg) in 
15 mL DMF for 1.5 h.  The mixture was shaken on a mechanical stirrer at room 
temperature for 1.5 h.  Completion of the coupling was confirmed by the Kaiser test.  
Glycine (0.8250 mmol, 254.3 mg), HOBt (0.8250 mmol, 111.5 mg), and DIC (0.8250 
mmol, 104.1 mg) were dissolved in 15 mL DMF and coupled to deprotected resin-bound 
amino acid on a mechanical stirrer at room temperature for 1.5 h.  4-
Carboxybenzaldehyde (0.8250 mmol, 123.8 mg), HOBt (0.8250 mmol, 111.5 mg), and 
DIC (0.8250 mmol, 104.1 mg) were dissolved in 15 mL DMF and coupled to the 
deprotected terminal glycine on a mechanical stirrer at room temperature for 1.5 h.  3,4-
Diaminobenzamidoxime (1.650 mmol, 274.2 mg) and 1,4-benzoquinone (0.165 mmol, 
17.8 mg) were dissolved in 15 mL DMF and coupled to resin-bound phenylaldehyde in a 
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scintillation vial for 5 h at 60 °C using an IKA-Werke mechanical stirrer and heating 
block.  Tin(II) chloride dehydrate (2.475 mmol, 558.5 mg) was dissolved in DMF (2.5 mL) 
and reacted with the resin-linked amidoxime using an IKA-Werke mechanical stirrer and 
heating block at 80 °C over 40 h with new aliquots of the Tin(II) chloride solution being 
added to the reaction mixture every 4 h.  The product was cleaved from the resin via 
shaking in a 1:1 solution of TFA:DCM for 1.5 h.  The resin was removed by filtration and 
rinsed with TFA and the filtrate-containing product was collected in tared vials, then the 
TFA and DCM were evaporated with a stream of nitrogen until only a couple of mL 
remained, which was then precipitated into cold ether.  The resulting solid was dissolved 
in MeOH and initially purified via flushing through a silica column (MeOH) to remove bulk 
impurities and then HPLC purified (A: H2O, 0.1% TFA; B: ACN, 0.1% TFA. Gradient: 0 
min, 80% A; 2 min, 80% A; 20 min, 20% A; 25 min, 0% A; 30 min, 0% A; 32 min, 80% A; 
35 min, 80% A).  Product was confirmed via LC/MS and 1H NMR. 
 
2.4.3.5. Synthesis of Diaminobenzamidoxime 
3,4-Diamino-N'-hydroxybenzimidamide, (1) 
 
Compound 1 was synthesized by mixing 3,4-diaminobenzonitrile (7.5 mmol, 1.0 
g) in ethanol (20 mL) and 20 equivalents 50% aqueous hydroxylamine (150 mmol, 4.95 
g) and refluxing for 5 hours.  The ethanol was evaporated under reduced pressure.  The 
compound was purified via column chromatography [EtOAc:MeOH (90:10)] and 
confirmed via LC/MS and 1H NMR.  (1.06 g, 85%); 1H NMR (DMSO-d6); δ4.45 (s, 2H), 
4.63 (s, 2H), 5.38 (s, 2H), 6.46 (d, J = 8 Hz, 1H), 6.71 (dd, J = 8.5 Hz, 1H), 6.85 (s, 1H), 
9.11 (s, 1H); LC/MS calcd for [M+H]+: C7H10N4O 167.1, found 167.3. 
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4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Model-BI-(+), (2) 
 
Compound 2 was synthesized by General Procedure 2.4.3.2.  (35 mg, 76%); 1H 
NMR (DMSO-d6); δ6.92 (s, 1H), 7.14 (s, 1H), 7.42 (dd, J = 9 Hz, 1H), 7.67 (d, J = 9 Hz, 
1H), 7.81 (d, J = 6 Hz, 2H), 7.90 (s, 1H), 8.06 (d, J = 9Hz, 2H), 8.39 (s, 2H), 9.05 (s, 2H); 
LC/MS calcd for [M+H]+: C15H13N5O 280.1, found 280.2. 
N-(2-amino-2-oxoethyl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, 
Gly-BI-(+), (3) 
 
 Compound 3 was obtained from 2 and Rink-Gly-Fmoc by General Procedure 
2.4.3.3.  (48 mg, 88%); 1H NMR (DMSO-d6); δ3.71 (d, J = 6 Hz, 2H), 6.93 (d, J = 8.5 Hz, 
1H), 7.28 (s, 1H), 7.55 (dd, J = 8 Hz, 1H), 7.67 (d, J = 7.5 Hz, 1H), 7.94 (t, J = 14 Hz, 
2H), 8.03 (s, 1H), 8.18 (d, J = 15 Hz, 2H), 8.69 (s, 2H), 8.86 (s, 1H), 9.14 (s, 2H); LC/MS 
calcd for [M+H]+: C17H16N6O2 337.1, found 337.3. 
N-(1-amino-1-oxopropan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamide, Ala-BI-(+), (4) 
 
Compound 4 was obtained from 2 and Rink-Ala-Fmoc by General Procedure 
2.4.3.3.  (42 mg, 74%); 1H NMR (DMSO-d6); δ1.43 (d, J = 7 Hz, 3H), 4.46 (m, 1H), 7.03 
(s, 1H), 7.43 (s, 1H), 7.70 (dd, J = 9 Hz, 1H), 7.83 (d, J = 8 Hz, 1H), 8.11 (d, J = 9 Hz, 
2H), 8.17 (s, 1H), 8.31 (d, J = 9 Hz, 2H), 8.58 (d, J = 7 Hz, 1H), 8.93 (s, 2H), 9.30 (s, 
1H); LC/MS calcd for [M+H]+: C18H18N6O2 351.1, found 351.4. 
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N-(1-amino-3-methyl-1-oxobutan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamide, Val-BI-(+), (5) 
 
Compound 5 was obtained from 2 and Rink-Val-Fmoc by General Procedure 
2.4.3.3.  (50 mg, 81%); 1H NMR (DMSO-d6); δ0.94 (d, J = 3Hz, 3H), 0.96 (d, J = 3 Hz, 
3H), 2.13 (m, 1H), 4.31 (m, 1H), 7.11 (s, 1H), 7.52 (s, 1H), 7.68 (dd, J = 10 Hz, 1H), 7.82 
(d, J = 8 Hz, 1H), 8.09 (d, J = 9 Hz, 2H), 8.17 (s, 1H), 8.30 (d, J = 8 Hz, 2H), 8.34 (s, 
1H), 8.95 (s, 1H), 9.30 (s, 1H); LC/MS calcd for [M+H]+: C20H22N6O2 379.2, found 379.3. 
N-(1-amino-4-methyl-1-oxopentan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamide, Leu-BI-(+), (6) 
 
Compound 6 was obtained from 2 and Rink-Leu-Fmoc by General Procedure 
2.4.3.3.  (49 mg, 76%); 1H NMR (DMSO-d6); δ0.90 (d, J = 6.5 Hz, 3H), 0.94 (d, J = 6.5 
Hz, 3H), 1.23 (t, J = 14 Hz, 2H), 1.73 (m, 1H), 4.48 (m, 1H), 6.93 (s, 1H), 7.28 (s, 1H), 
7.69 (dd, J = 9.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 8.10 (d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 
8.32 (d, J = 8.5 Hz, 2H), 8.76 (d, J = 8 Hz, 1H), 9.12 (s, 2H), 9.30 (s, 2H); LC/MS calcd 
for [M+H]+: C21H24N6O2 393.2, found 393.2. 
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N-(1-amino-3-methyl-1-oxopentan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamide, Ile-BI-(+), (7) 
 
Compound 7 was obtained from 2 and Rink-Ile-Fmoc by General Procedure 
2.4.3.3.  (47 mg, 73%); 1H NMR (DMSO-d6); δ0.80 (t, J = 13 Hz, 3H), 0.87 (d, J = 6.5 Hz, 
3H), 1.15 (m, 2H), 1.47 (m, 1H), 4.28 (t, J = 15 Hz, 1H), 7.04 (s, 1H), 7.47 (s, 1H), 7.52 
(d, J = 8 Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 7.93 (d, J = 8 Hz, 1H), 8.05 (d, J = 8.5 Hz, 
2H), 8.26 (d, J = 8.5 Hz, 2H), 8.30 (d, J = 8.5 Hz, 1H), 8.80 (s, 2H), 9.24 (s, 2H); LC/MS 
calcd for [M+H]+: C21H24N6O2 393.2, found 393.2. 
N-(1-amino-4-(methylthio)-1-oxobutan-2-yl)-4-(6-carbamimidoyl-1H-
benzo[d]imidazol-2-yl)benzamide, Met-BI-(+), (8) 
 
Compound 8 was obtained from 2 and Rink-Met-Fmoc by General Procedure 
2.4.3.3.  (49 mg, 73%); 1H NMR (DMSO-d6); δ1.94 (s, 3H), 2.44 (t, J = 11 Hz, 2H), 3.19 
(q, J = 15.5 Hz, 2H), 4.40 (m, 1H), 6.97 (s, 1H), 7.35 (s, 1H), 7.56 (dd, J = 10 Hz, 1H), 
7.70 (d, J = 8.5 Hz, 1H), 7.98 (t, J = 15.5 Hz, 2H), 8.04 (s, 1H), 8.19 (t, J = 15 Hz, 2H), 
8.48 (d, J = 12 Hz, 1H), 8.83 (s, 2H), 9.17 (s, 2H); LC/MS calcd for [M+H]+: C20H22N6O2S 
411.2, found 411.5. 
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1-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzoyl)pyrrolidine-2-
carboxamide, Pro-BI-(+), (9) 
 
Compound 9 was obtained from 2 and Rink-Pro-Fmoc by General Procedure 
2.4.3.3.  (49 mg, 79%); 1H NMR (DMSO-d6); δ1.24 (m, 2H), 1.88 (m, 2H), 3.62 (t, J = 14 
Hz, 2H), 4.40 (t, J = 14 Hz, 1H), 7.17 (s, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.76 (d, J = 8 Hz, 
1H), 7.81 (d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.24 (t, J = 15.5 Hz, 1H), 8.30 (t, J = 14.5 Hz, 
2H), 9.08 (s, 1H), 9.30 (s, 1H); LC/MS calcd for [M+H]+: C20H20N6O2 377.2, found 377.5. 
N-(1-amino-1-oxo-3-phenylpropan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-
2-yl)benzamide, Phe-BI-(+), (10) 
 
 Compound 10 was obtained from 2 and Rink-Phe-Fmoc by General Procedure 
2.4.3.3.  (45 mg, 64%); 1H NMR (DMSO-d6); δ2.55 (t, J = 11 Hz, 2H), 4.68 (m, 1H), 7.02 
(s, 1H), 7.17 (m, 1H), 7.22 (q, J = 8 Hz, 2H), 7.27 (t, J = 15 Hz, 2H), 7.61 (s, 1H), 7.69 
(dd, J = 8.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 8.01 (d, J = 7.5 Hz, 2H), 8.17 (s, 1H), 8.29 
(t, J = 15 Hz, 2H), 8.88 (d, J = 8 Hz, 1H), 8.98 (s, 2H), 9.30 (s, 2H); LC/MS calcd for 
[M+H]+: C24H22N6O2 427.2, found 427.4. 
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N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-4-(6-carbamimidoyl-1H-benzo[d]imidazol-
2-yl)benzamide, Thr-BI-(+), (11) 
 
 Compound 11 was obtained from 2 and Rink-Thr(tBu)-Fmoc by General 
Procedure 2.4.3.3.  (48 mg, 77%); 1H NMR (DMSO-d6); δ1.13 (d, J = 6.5 Hz, 3H), 4.12 
(t, J = 10.5 Hz, 1H), 4.38 (q, J = 8.7 Hz, 1H), 6.94 (s, 1H), 7.27 (s, 1H), 7.45 (s, 1H), 7.69 
(d, J = 8 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 2H), 8.26 (d, J = 8.5 Hz, 
1H), 8.34 (d, J = 8 Hz, 2H), 8.43 (s, 1H), 8.88 (s, 2H), 9.30 (s, 2H); LC/MS calcd for 
[M+H]+: C19H20N6O3 381.2, found 381.4. 
2-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamido)succinamide, Asn-BI-
(+), (12) 
 
 Compound 12 was obtained from 2 and Rink-Asn(Trt)-Fmoc by General 
Procedure 2.4.3.3.  (51 mg, 79%); 1H NMR (DMSO-d6); δ2.61 (d, J = 8.5 Hz, 2H), 4.73 
(m, 1H), 7.04 (s, 1H), 7.14 (s, 1H), 7.24 (s, 2H), 7.69 (dd, J = 8.5 Hz, 1H), 7.83 (d, J = 
8.5 Hz, 1H), 8.07 (d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.32 (d, J = 8 Hz, 2H), 8.67 (d, J = 8 
Hz,  2H), 9.06 (s, 2H), 9.30 (s, 2H); LC/MS calcd for [M+H]+: C19H19N7O3 394.2, found 
394.3. 
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2-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamido)pentanediamide, Gln-
BI-(+), (13) 
 
Compound 13 was obtained from 2 and Rink-Gln(Trt)-Fmoc by General 
Procedure 2.4.3.3.  (49 mg, 73%); 1H NMR (DMSO-d6); δ1.95 (m, 2H), 2.36 (m, 2H), 
4.41 (m, 1H), 7.02 (s, 1H), 7.12 (s, 2H), 7.22 (s, 1H), 7.69 (d, J = 9.5 Hz, 1H), 7.83 (d, J 
= 8.5 Hz, 1H), 8.11 (t, J = 14 Hz, 2H), 8.17 (s, 1H), 8.32 (t, J = 14.5 Hz, 2H), 8.97 (s, 
2H), 9.28 (s, 1H), 9.30 (s, 2H); %). LC/MS calcd for [M+H]+: C20H21N7O3 408.2, found 
408.5. 
N-(1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-4-(6-carbamimidoyl-1H-
benzo[d]imidazol-2-yl)benzamide, Tyr-BI-(+), (14) 
 
 Compound 14 was obtained from 2 and Rink-Tyr(tBu)-Fmoc by General 
Procedure 2.4.3.3.  (44 mg, 61%); 1H NMR (DMSO-d6); δ2.55 (t, J = 11 Hz, 2H), 4.58 
(m, 1H), 6.65 (t, J = 18 Hz, 2H), 7.13 (t, J = 18 Hz, 2H), 7.25 (s, 1H), 7.57 (s, 1H), 7.69 
(d, J = 8.5 Hz, 1H), 7.83 (d, J = 8 Hz, 1H), 8.02 (d, J = 8 Hz, 2H), 8.17 (s, 1H), 8.29 (t, J 
= 17 Hz, 2H), 8.59 (d, J = 8.5 Hz, 1H), 9.07 (s, 2H), 9.30 (s, 2H); LC/MS calcd for 
[M+H]+: C24H22N6O3 443.2, found 443.5. 
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4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)-N-(1,6-diamino-1-oxohexan-2-
yl)benzamide, Lys-BI-(+), (15) 
 
Compound 15 was obtained from 2 and Rink-Lys(Boc)-Fmoc by General 
Procedure 2.4.3.3.  (43 mg, 64%); 1H NMR (DMSO-d6); δ1.44 (m, 2H), 1.58 (t, J = 14 
Hz, 2H), 1.78 (m, 2H), 2.79 (q, J = 8.5 Hz, 2H), 4.40 (q, J = 8.5 Hz, 1H), 7.23 (s, 1H), 
7.33 (s, 1H), 7.71 (dd, J = 8.5 Hz, 1H), 7.83 (s, 2H), 7.89 (d, J = 8 Hz, 1H), 8.11 (d, J = 
8.5 Hz, 2H), 8.19 (s, 1H), 8.35 (d, J = 8 Hz, 2H), 8.59 (d, J = 8.5 Hz, 1H), 8.95 (s, 2H), 
9.34 (s, 2H); LC/MS calcd for [M+H]+: C21H25N7O2 408.2, found 408.5. 
N-(1-amino-5-guanidino-1-oxopentan-2-yl)-4-(6-carbamimidoyl-1H-
benzo[d]imidazol-2-yl)benzamide, Arg-BI-(+), (16) 
 
Compound 16 was obtained from 2 and Rink-Arg(Pbf)-Fmoc by General 
Procedure 2.4.3.3.  (41 mg, 58%); 1H NMR (DMSO-d6); δ1.58 (m, 2H), 1.75 (m, 2H), 
3.12 (q, J = 12.2 Hz, 2H), 4.40 (m, 1H), 7.06 (s, 1H), 7.12 (s, 1H), 7.23 (s, 1H), 7.33 (s, 
1H), 7.58 (s, 2H), 7.68 (dd, J = 9 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 8.05 (t, J = 14 Hz, 
2H), 8.15 (s, 1H), 8.26 (t, J = 13 Hz, 2H), 8.62 (d, J = 7.5 Hz, 1H), 8.92 (s, 2H), 9.34 (s, 
2H); LC/MS calcd for [M+H]+: C21H25N9O2 436.2, found 436.5. 
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4-Amino-3-(4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamido)-4-
oxobutanoic acid, Asp-BI-(+), (17) 
 
 Compound 17 was obtained from 2 and Rink-Asp(OtBu)-Fmoc by General 
Procedure 2.4.3.3.  (50 mg, 78%); 1H NMR (DMSO-d6); δ2.20 (m, 2H), 4.63 (m, 1H), 
6.75 (s, 1H), 6.96 (s, 1H), 7.05 (s, 1H), 7.47 (dd, J = 8 Hz, 1H), 7.62 (d, J = 10 Hz, 1H), 
7.88 (d, J = 8 Hz, 2H), 7.97 (s, 1H), 8.11 (d, J = 7.5 Hz, 2H), 8.36 (d, J = 6.5 Hz, 1H), 
8.75 (s, 2H), 9.12 (s, 2H); LC/MS calcd for [M+H]+: C19H18N6O4 395.1, found 395.1. 
5-Amino-4-(4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamido)-5-
oxopentanoic acid, Glu-BI-(+), (18) 
 
 Compound 18 was obtained from 2 and Rink-Glu(OtBu)-Fmoc by General 
Procedure 2.4.3.3.  (48 mg, 72%); 1H NMR (DMSO-d6); δ1.75 (m, 2H), 2.14 (m, 2H), 
4.22 (m, 1H), 6.85 (s, 1H), 6.95 (s, 1H), 7.05 (s, 1H), 7.48 (dd, J = 8.5 Hz, 1H), 7.61 (d, J 
= 8.5 Hz, 1H), 7.88 (t, J = 14 Hz, 2H), 7.96 (s, 1H), 8.11 (t, J = 14.5 Hz, 2H), 8.58 (d, J = 
7.5 Hz, 1H), 8.95 (s, 2H), 9.09 (s, 2H); LC/MS calcd for [M+H]+: C20H20N6O4 409.2, found 
409.4. 
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N-(2-((2-amino-2-oxoethyl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-1H-
benzo[d]imidazol-2-yl)benzamide, Gly-Gly-BI-(+), (19) 
 
 Compound 19 was obtained from 2 and Rink-Gly-Gly-Fmoc by General 
Procedure 2.4.3.4.  (60 mg, 93%); 1H NMR (DMSO-d6); δ3.66 (d, J = 6 Hz, 2H), 3.95 (d, 
J = 6.5 Hz, 2H), 7.11 (s, 1H), 7.26 (s, 1H), 7.68 (dd, J = 8.5 Hz, 1H), 7.82 (d, J = 8.5 Hz, 
1H), 8.10 (d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.21 (t, J = 12 Hz, 1H), 8.32 (d, J = 8.5 Hz, 
2H), 8.88 (s, 2H), 8.97 (t, J = 11.5 Hz, 1H), 9.29 (s, 2H); LC/MS calcd for [M+H]+: 
C19H19N7O3 394.2, found 394.3. 
N-(2-((1-amino-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-1H-
benzo[d]imidazol-2-yl)benzamide, Ala-Gly-BI-(+), (20) 
 
 Compound 20 was obtained from 2 and Rink-Ala-Gly-Fmoc by General 
Procedure 2.4.3.4.  (55 mg, 82%); 1H NMR (DMSO-d6); δ1.23 (d, J = 8 Hz, 3H), 3.94 (d, 
J = 8.5 Hz, 2H), 4.24 (p, 1H), 7.05 (s, 1H), 7.32 (s, 1H), 7.69 (dd, J = 8.5 Hz, 1H), 7.82 
(d, J = 8.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 8.10 (t, J = 12 Hz, 1H), 8.17 (s, 1H), 8.32 (d, 
J = 8.5 Hz, 2H), 8.92 (t, J = 11.5 Hz, 1H), 9.01 (s, 2H), 9.30 (s, 2H); LC/MS calcd for 
[M+H]+: C20H21N7O3 408.2, found 408.2. 
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N-(2-((1-amino-3-methyl-1-oxobutan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-
1H-benzo[d]imidazol-2-yl)benzamide, Val-Gly-BI-(+), (21) 
 
Compound 21 was obtained from 2 and Rink-Val-Gly-Fmoc by General 
Procedure 2.4.3.4.  (62 mg, 87%); 1H NMR (DMSO-d6); δ0.84 (d, J = 7 Hz, 3H), 0.87 (d, 
J = 7 Hz, 3H), 1.99 (m, 1H), 3.99 (d, J = 7.5 Hz, 2H), 4.16 (t, J = 15 Hz, 1H), 7.07 (s, 
1H), 7.42 (s, 1H), 7.68 (dd, J = 8.5 Hz, 1H), 7.82 (t, J = 13.5 Hz, 1H), 7.84 (s, 1H), 8.08 
(d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.32 (d, J = 8.5 Hz, 2H), 8.90 (s, 2H), 8.91 (s, 1H), 9.29 
(s, 2H); LC/MS calcd for [M+H]+: C22H25N7O3 436.2, found 436.3. 
N-(2-((1-amino-4-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-
1H-benzo[d]imidazol-2-yl)benzamide, Leu-Gly-BI-(+), (22) 
 
 Compound 22 was obtained from 2 and Rink-Leu-Gly-Fmoc by General 
Procedure 2.4.3.4.  (63 mg, 85%); 1H NMR (DMSO-d6); δ0.86 (d, J = 9.5 Hz, 3H), 0.89 
(d, J = 9.5 Hz, 3H), 1.48 (t, J = 10 Hz, 2H), 1.60 (m, 1H), 3.96 (d, J = 5.5 Hz, 2H), 4.25 
(q, J = 14.5 Hz, 1H), 7.02 (s, 1H), 7.34 (s, 1H), 7.68 (dd, J = 8 Hz, 1H), 7.82 (s, 1H), 8.04 
(d, J = 8.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.32 (d, J = 8.5 Hz, 2H), 8.91 
(t, J = 12.5 Hz, 1H), 8.96 (s, 2H), 9.29 (s, 2H); LC/MS calcd for [M+H]+: C23H27N7O3 
450.2, found 450.2. 
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N-(2-((1-amino-3-methyl-1-oxopentan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-
1H-benzo[d]imidazol-2-yl)benzamide, Ile-Gly-BI-(+), (23) 
 
 Compound 23 was obtained from 2 and Rink-Ile-Gly-Fmoc by General Procedure 
2.4.3.4.  (67 mg, 91%); 1H NMR (DMSO-d6); δ0.82 (t, J = 13 Hz, 3H), 0.86 (d, J = 9 Hz, 
3H), 1.08 (m, 2H), 1.44 (m, 1H), 3.99 (t, J = 11 Hz, 2H), 4.19 (t, J = 15.5 Hz, 1H), 7.07 
(s, 1H), 7.43 (s, 1H), 7.69 (d, J = 9 Hz, 1H), 7.82 (s, 1H), 7.86 (d, J = 9 Hz, 1H), 8.08 (d, 
J = 8.5 Hz, 2H), 8.17 (s, 1H), 8.32 (d, J = 8.5 Hz, 2H), 8.89 (s, 2H), 8.91 (t, J = 11.5 Hz, 
1H), 9.30 (s, 2H); LC/MS calcd for [M+H]+: C23H27N7O3 450.2, found 450.4. 
N-(2-((1-amino-4-(methylthio)-1-oxobutan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Met-Gly-BI-(+), (24) 
 
 Compound 24 was obtained from 2 and Rink-Met-Gly-Fmoc by General 
Procedure 2.4.3.4.  (69 mg, 90%); 1H NMR (DMSO-d6); δ3.88 (m, 2H), 3.97 (m, 2H), 
4.50 (m, 2H), 6.89 (s, 1H), 7.14 (s, 1H), 7.18 (s, 1H), 7.34 (s, 1H), 7.69 (dd, J = 8.5 Hz, 
1H), 7.83 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 8.18 (s, 1H), 8.26 (d, J = 8 Hz, 
1H), 8.33 (d, J = 8.5 Hz, 2H), 8.96 (s, 2H), 9.00 (t, J = 11.5 Hz, 1H), 9.30 (s, 2H); LC/MS 
calcd for [M+H]+: C22H25N7O3S 468.1, found 468.2. 
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1-(2-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamido)acetyl)pyrrolidine-
2-carboxamide, Pro-Gly-BI-(+), (25) 
 
Compound 25 was obtained from 2 and Rink-Pro-Gly-Fmoc by General 
Procedure 2.4.3.4.  (65 mg, 91%); 1H NMR (DMSO-d6); δ1.76 (m, 2H), 1.88 (m, 2H), 
3.39 (q, J = 17 Hz, 2H), 3.95 (d, J = 5.5 Hz, 2H), 4.08 (d, J = 8.5 Hz, 1H), 6.80 (s, 1H), 
7.11 (s, 1H), 7.53 (dd, J = 8.5 Hz, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.93 (d, J = 8.5 Hz, 2H), 
8.01 (s, 1H), 8.16 (d, J = 8 Hz, 2H), 8.61 (t, J = 11 Hz, 1H), 8.82 (s, 2H), 9.14 (s, 2H); 
LC/MS calcd for [M+H]+: C22H23N7O3 434.2, found 434.3. 
N-(2-((1-amino-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-
1H-benzo[d]imidazol-2-yl)benzamide, Phe-Gly-BI-(+), (26) 
 
 Compound 26 was obtained from 2 and Rink-Phe-Gly-Fmoc by General 
Procedure 2.4.3.4.  (61 mg, 77%); 1H NMR (DMSO-d6); δ3.04 (dd, J = 14 Hz, 2H), 3.81 
(d, J = 10.5 Hz, 2H), 4.46, 4.48 (ABd, J = 8.8 Hz, 1H), 7.14 (s, 1H), 7.18 (d, J = 5 Hz, 
1H), 7.24 (d, J = 4 Hz, 4H), 7.45 (s, 1H), 7.70 (dd, J = 8.5 Hz, 1H), 7.82 (d, J = 7 Hz, 
1H), 8.06 (d, J = 8.5 Hz, 2H), 8.12 (d, J = 8.5 Hz, 1H), 8.18 (s, 1H), 8.32 (d, J = 8 Hz, 
2H), 8.83 (s, 2H), 8.88 (t, J = 12 Hz, 1H), 9.29 (s, 2H); LC/MS calcd for [M+H]+: 
C26H25N7O3 484.2, found 484.3. 
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N-(2-((1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Trp-Gly-BI-(+), (27) 
 
 Compound 27 was obtained from 2 and Rink-Trp(Boc)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (63 mg, 74%); 1H NMR (DMSO-d6); δ2.93 (m, 2H), 3.92 (d, J = 9 Hz, 
2H), 4.43 (q, J = 9.2 Hz, 1H), 6.89 (t, J = 15 Hz, 1H), 6.96 (t, J = 16 Hz, 1H), 7.05 (d, J = 
13 Hz, 2H), 7.24 (d, J = 8 Hz, 1H), 7.36 (s, 1H), 7.52 (d, J =7.5 Hz, 1H), 7.61 (dd, J = 8.5 
Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 8.5 Hz, 2H), 8.02 (d, J = 8.5 Hz, 1H), 8.10 
(s, 1H), 8.25 (d, J = 8.5 Hz, 2H), 8.81 (t, J = 13 Hz, 1H), 8.91 (s, 2H), 9.22 (s, 2H), 10.71 
(s, 1H); LC/MS calcd for [M+H]+: C28H26N8O3 523.2, found 523.3. 
N-(2-((1-amino-3-hydroxy-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Ser-Gly-BI-(+), (28) 
 
 Compound 28 was obtained from 2 and Rink-Ser(tBu)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (41 mg, 59%); 1H NMR (DMSO-d6); δ3.61 (m, 2H), 3.98 (m, 2H), 
4.24 (q, J = 8.5 Hz, 1H), 7.15 (s, 1H), 7.31 (s, 1H), 7.69 (dd, J = 8.5 Hz, 1H), 7.82 (d, J = 
8.5 Hz, 1H), 7.98 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 8.5 Hz, 2H), 8.18 (s, 1H), 8.33 (d, J = 
8.5 Hz, 2H), 8.95 (t, J = 10.5 Hz, 1H), 8.97 (s, 1H), 9.30 (s, 2H); LC/MS calcd for [M+H]+: 
C20H21N7O4 424.2, found 424.3. 
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N-(2-((1-amino-3-hydroxy-1-oxobutan-2-yl)amino)-2-oxoethyl)-4-(6-carbamimidoyl-
1H-benzo[d]imidazol-2-yl)benzamide, Thr-Gly-BI-(+), (29) 
 
 Compound 29 was obtained from 2 and Rink-Thr(tBu)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (64 mg, 89%); 1H NMR (DMSO-d6); δ0.88 (d, J = 6.5 Hz, 3H), 1.14 
(m, 1H), 3.96 (m, 2H), 5.02 (t, J = 12 Hz, 1H), 6.97 (s, 1H), 7.06 (s, 1H), 7.53 (dd, J = 9.5 
Hz, 1H), 7.62 (s, 1H), 7.66 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 9 Hz, 1H), 7.93 (d, J = 8.5 Hz, 
2H), 8.01 (s, 1H), 8.16 (d, J = 8 Hz, 2H), 8.19 (s, 1H), 8.81 (t, J = 11.5 Hz, 2H), 9.13 (s, 
2H); LC/MS calcd for [M+H]+: C21H23N7O4 438.2, found 438.2. 
2-(2-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamido)acetamido)succinamide, Asn-Gly-BI-(+), (30) 
 
 Compound 30 was obtained from 2 and Rink-Asn(Trt)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (51 mg, 69%); 1H NMR (DMSO-d6); δ1.74 (m, 2H), 3.89 (m, 2H), 
4.24 (q, J = 10.5 Hz, 1H), 7.06 (s, 1H), 7.29 (s, 1H), 7.61 (dd, J = 8.5 Hz, 1H), 7.75 (d, J 
= 8.5 Hz, 1H), 8.01 (d, J = 8.5 Hz, 2H), 8.06 (d, J = 8.5 Hz, 1H), 8.10 (s, 1H), 8.25 (d, J = 
8.5 Hz, 2H), 8.87 (t, J = 11.5 Hz, 1H), 8.92 (s, 2H), 9.23 (s, 2H); LC/MS calcd for [M+H]+: 
C21H22N8O4 451.2, found 451.3. 
 
 
 
 
 
 
61 
 
2-(2-(4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamido)acetamido)pentanediamide, Gln-Gly-BI-(+), (31) 
 
 Compound 31 was obtained from 2 and Rink-Gln(Trt)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (56 mg, 73%); 1H NMR (DMSO-d6); δ1.83 (m, 2H), 2.00 (t, J = 14 
Hz, 2H), 4.01 (t, J = 10 Hz, 2H), 4.24 (q, J = 8.2 Hz, 1H), 6.80 (s, 1H), 7.15 (s, 1H), 7.33 
(s, 2H), 7.73 (dd, J = 8.5 Hz, 1H), 7.87 (d, J = 8 Hz, 1H), 8.13 (d, J = 8.5 Hz, 2H), 8.17 
(d, J = 8.5 Hz, 1H), 8.22 (s, 1H), 8.37 (d, J = 8.5 Hz, 2H), 8.93 (s, 2H), 8.98 (t, J = 11.5 
Hz, 1H), 9.34 (s, 2H); LC/MS calcd for [M+H]+: C22H24N8O4 465.2, found 465.2. 
N-(2-((1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Tyr-Gly-BI-(+), (32) 
 
 Compound 32 was obtained from 2 and Rink-Tyr(tBu)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (53 mg, 65%); 1H NMR (DMSO-d6); δ2.67 (d, J = 9 Hz, 1H), 3.56 (d, 
J = 11 Hz, 2H), 3.74 (d, J = 10.5 Hz, 2H), 4.12 (m, 1H), 6.37 (d, J = 8.5 Hz, 2H), 6.77 (d, 
J = 8.5 Hz, 2H), 6.85 (s, 1H), 7.16 (s, 1H), 7.45 (dd, J = 8.5 Hz, 1H), 7.58 (d, J = 8 Hz, 
1H), 7.80 (d, J = 8 Hz, 1H), 7.83 (d, J = 8.5 Hz, 2H), 7.93 (s, 1H), 8.09 (d, J = 8.5 Hz, 
2H), 8.65 (t, J = 12 Hz, 1H), 8.74 (s, 2H), 9.06 (s, 2H); LC/MS calcd for [M+H]+: 
C26H25N7O4 500.2, found 500.3. 
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N-(2-((1-amino-3-mercapto-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Cys-Gly-BI-(+), (33) 
 
 Compound 33 was obtained from 2 and Rink-Cys(Trt)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (31 mg, 44%); 1H NMR (DMSO-d6); δ2.11 (t, J = 17.5 Hz, 1H), 2.65 
(m, 2H), 3.81 (d, J = 7.7 Hz, 2H), 4.18 (m, 1H), 7.07 (s, 1H), 7.25 (s, 1H), 7.50 (dd, J = 
8.5 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.91 (d, J = 8.5 Hz, 2H), 7.97 (s, 1H), 7.99 (s, 1H), 
8.14 (d, J = 8.5 Hz, 2H), 8.79 (s, 2H), 8.81 (s, 1H), 9.11 (s, 2H); LC/MS calcd for [M+H]+: 
C20H21N7O3S 440.1, found 440.1. 
4-(6-Carbamimidoyl-1H-benzo[d]imidazol-2-yl)-N-(2-((1,6-diamino-1-oxohexan-2-
yl)amino)-2-oxoethyl)benzamide, Lys-Gly-BI-(+), (34) 
 
 Compound 34 was obtained from 2 and Rink-Lys(Boc)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (72 mg, 94%); 1H NMR (DMSO-d6); δ1.10 (m, 2H), 1.30 (m, 2H), 
1.49 (m, 2H), 2.54 (t, J = 12 Hz, 2H), 3.74 (d, J = 5.5 Hz, 2H), 3.97 (q, J = 8.5 Hz, 1H), 
6.88 (s, 1H), 7.14 (s, 1H), 7.40 (s, 2H), 7.47 (dd, J = 8.5 Hz, 1H), 7.60 (d, J = 8.5 Hz, 
1H), 7.80 (s, 1H), 7.86 (d, J = 8 Hz, 2H), 7.95 (s, 1H), 8.10 (d, J = 8.5 Hz, 2H), 8.72 (t, J 
= 11.5 Hz, 1H), 8.75 (s, 2H), 9.07 (s, 2H); %). LC/MS calcd for [M+H]+: C23H28N8O3 
465.2, found 465.2. 
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N-(2-((1-amino-5-guanidino-1-oxopentan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, Arg-Gly-BI-(+), (35) 
 
 Compound 35 was obtained from 2 and Rink-Arg(Pbf)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (63 mg, 78%); 1H NMR (DMSO-d6); δ1.30 (m, 2H), 1.53 (m, 2H), 
2.89 (t, J = 12.5 Hz, 2H), 3.75 (d, J = 5.5 Hz, 2H), 4.03 (m, 1H), 6.93 (s, 1H), 7.19 (s, 
1H), 7.38 (s, 1H), 7.48 (dd, J = 8.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 8.5 Hz, 
2H), 7.91 (d, J = 8 Hz, 1H), 7.97 (s, 1H), 8.12 (d, J = 8.5 Hz, 2H), 8.74 (t, J = 11.5 Hz, 
1H), 8.84 (s, 2H), 9.09 (s, 2H); LC/MS calcd for [M+H]+: C23H28N10O3 493.2, found 493.3. 
N-(2-((1-amino-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-4-(6-
carbamimidoyl-1H-benzo[d]imidazol-2-yl)benzamide, His-Gly-BI-(+), (36) 
 
 Compound 36 was obtained from 2 and Rink-His(Trt)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (47 mg, 61%); 1H NMR (DMSO-d6); δ2.95 (m, 1H), 3.18 (d, J = 10.5 
Hz, 2H), 3.89 (d, J = 5.5 Hz, 1H), 3.93 (d, J = 6 Hz, 2H), 4.54 (m, 1H), 7.33 (s, 1H), 7.38 
(s, 1H), 7.44 (s, 1H), 7.69 (dd, J = 8.5 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 8.5 
Hz, 2H), 8.18 (s, 1H), 8.34 (d, J = 8.5 Hz, 2H), 8.99 (s, 1H), 9.00 (s, 1H), 9.30 (s, 1H), 
14.20 (s, 1H); LC/MS calcd for [M+H]+: C23H23N9O3 474.2, found 474.4. 
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4-Amino-3-(2-(4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamido)acetamido)-4-oxobutanoic acid, Asp-Gly-BI-(+), (37) 
 
 Compound 37 was obtained from 2 and Rink-Asp(OtBu)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (63 mg, 85%); 1H NMR (DMSO-d6); δ2.62 (m, 2H), 3.87 (m, 2H), 
4.46 (q, J = 13. 5 Hz, 1H), 7.10 (s, 1H), 7.15 (s, 1H), 7.60 (dd, J = 8.5 Hz, 1H), 7.73 (d, J 
= 8.5 Hz, 1H), 7.99 (d, J = 8.5 Hz, 2H), 8.08 (s, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.23 (d, J = 
8 Hz, 2H), 8.85 (s, 2H), 8.89 (t, J = 11 Hz, 1H), 9.21 (s, 2H), 12.27 (s, 1H); LC/MS calcd 
for [M+H]+: C21H21N7O5 452.2, found 452.1. 
5-Amino-4-(2-(4-(6-carbamimidoyl-1H-benzo[d]imidazol-2-
yl)benzamido)acetamido)-5-oxopentanoic acid, Glu-Gly-BI-(+), (38) 
 
 Compound 38 was obtained from 2 and Rink-Glu(OtBu)-Gly-Fmoc by General 
Procedure 2.4.3.4.  (54 mg, 71%); 1H NMR (DMSO-d6); δ1.79 (m, 2H), 2.24 (t, J = 15 
Hz, 2H), 3.95 (m, 2H), 4.23 (q, J = 8 Hz, 1H), 7.13 (s, 1H), 7.36 (s, 1H), 7.70 (dd, J = 8.5 
Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 8.08 (d, J = 7.5 Hz, 2H), 8.11 (s, 1H), 8.18 (s, 1H), 
8.33 (d, J = 8.5 Hz, 2H), 8.94 (t, J = 11 Hz, 1H), 9.00 (s, 2H), 9.32 (s, 2H), 12.2 (s, 1H); 
LC/MS calcd for [M+H]+: C22H23N7O5 466.2, found 466.3. 
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CHAPTER 3. PRELIMINARY SCREENING OF DNA BINDING ACTIVITY 
 
3.1. Overview 
 A new series of amino acid-benzimidazole-amidine and di-amino acid-
benzimidazole-amidine conjugates were designed and synthesized in our laboratory.  To 
analyze the relative DNA binding affinity of these compounds, a microplate-based 
fluorescence intercalator displacement (HT-FID) assay was used.  This chapter will 
introduce the HT-FID assay developed by Boger et al. and illustrate its validation 
process.  We will use calf thymus DNA along with ethidium bromide as a fluorescence 
indicator to establish the relative binding affinity of our amino acid-benzimidazole-
amidine conjugates.1-5 
 
3.2. HT-FID Assay 
 There are a number of techniques such as footprinting and affinity cleavage6 
used to analyze the DNA-binding interactions of small molecules; unfortunately, most of 
these methods are challenging and time-consuming,7 making analysis of large catalogs 
of compounds difficult.  The HT-FID assay (Figure 3.1)8, addresses the ease-of-use 
challenges of other methods and utilizes DNA treated with ethidium bromide to yield 
fluorescence upon DNA-ethidium bromide binding.  Addition of DNA-binding compound 
displaces the ethidium bromide, resulting in a decrease in the fluorescence.  The percent 
fluorescence decrease is directly related to the extent of DNA-ligand binding and can 
show the relative binding affinity of our synthesized compounds.  FID is commonly 
employed using a library of all possible 4- or 5-bp hairpin oligonucleotides to establish 
the DNA-ligand binding site-selectivity of the target compound, but calf thymus DNA 
(CT-DNA) has the advantage of being a cost-effective high-throughput substrate 
approximating all possible combinations of base pairs and can be used to establish the 
relative DNA binding of a group of compounds.1  It is important to note the analysis of 
our amino acid-benzimidazole-amidine conjugates is preliminary, and as such, the focus 
of this section is on the relative binding as determined using CT-DNA rather than 
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determining the site-selectivity or absolute Kbinding of our conjugates with a 4- or 5-
basepair library.  The resulting DNA-binding discussed henceforth shows the relative 
rank-order of the amino acid-benzimidazole-amidine conjugates as compared to each 
other in calf thymus DNA, allowing our group to establish the order of DNA-binding 
activity for the conjugates. 
 
 
Figure 3.1. Depiction of the HT-FID assay process. 
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 The HT-FID assay using CT-DNA has been used to analyze a commercially-
available chemical library of 60,000 compounds to determine which of the compounds 
exhibited DNA-binding ability.1  Although a determination of site selectivity was not our 
focus, the FID assay has been validated by analyzing the DNA binding site selectivity of 
several well studied A/T-rich minor groove binding agents such as netropsin, distamycin, 
Hoechst 33258, and RT 294 and the assay could be used in the future to further analyze 
the specific binding sites of our compounds.  The HT-FID assay using CT-DNA has the 
potential to be widely applicable in the discovery of new DNA binding agents, making it 
an ideal choice to quickly establish the relative binding of our amino acid-benzimidazole-
amidine conjugates. 
 
3.2.1. HT-FID Assay Validation 
 Due to its well-behaved performance in the FID assay, netropsin can be used as 
a compound in the validation of the assay.8,9  Netropsin has previously been evaluated 
using the FID assay with both 4- and 5-bp libraries of oligonucleotides as well as with 
CT-DNA using ethidium bromide as the reporting fluorophores, thus providing sufficient 
information to validate the assay.  Therefore, netropsin was analyzed along with our 
amino acid-benzimidazole-amidine conjugates to validate the assay.  Distamycin, 
another compound that has been extensively studied using the 4- and 5-bp libraries was 
also used in our validation to provide a second well-studied DNA binder for comparison 
of our conjugates.  For our validation, netropsin and distamycin were carried out in the 
assay side-by-side with our conjugates at concentrations of 0.75, 1.5, and 3.0 μM with 
10 μM CT-DNA and 4.5 μM ethidium bromide, as previously described.1  
 To assess the validity of our assay using ethidium bromide-bound calf thymus 
DNA, Z′ scores10 were determined using netropsin and distamycin as positive controls 
due to their well understood binding and wells containing a buffer blank were used as a 
negative control.  To define a screening window for the HT-FID assay, µc- and µc+ are 
denoted as the means of the negative control signal and positive control signal, 
respectively.  The standard deviations of the signals are denoted as σc- and  σc+, 
respectively.  The Z′-factor can be used for quality assessment in assay development 
and optimization and is appropriate for evaluating the overall quality of the assay.  For 
example, if the Z′ value is small (negative or near zero), the assay conditions have not 
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been optimized or the assay is not feasible for generating useful data.  An excellent 
assay has a Z′ score of 0.5 to 1, with 1 being an ideal assay and scores ranging down to 
0 only being applicable as a “yes or no” type of assay.10  In our Z′ analysis, the negative 
controls provide a maximum percent fluorescence possible from the assay and the 
positive controls provide a maximum decrease in fluorescence possible from a strong 
DNA binding agent, therefore determining the dynamic range of the assay.  The 
observed data for netropsin and distamycin is summarized in Table 3.1.  
 
Table 3.1. Z′-score analysis of netropsin and distamycin. 
       
             
          
 
Netropsin Distamycin 
Concentration Percent F Z′-score Concentration Percent F Z′-score 
0.75 μM 77% 0.75 0.75 μM 84% 0.66 
1.50 μM 64% 0.60 1.50 μM 70% 0.50 
3.00 μM 59% 0.47 3.00 μM 63% 0.43 
 
Using the data above, it was determined that netropsin could serve as a positive 
control for the assay when analyzing our conjugates due to the Z′-score generally falling 
into the acceptable range of 0.5 to 1.  Distamycin also appeared to be a suitable control, 
presenting similar Z′-scores as netropsin, and was also run in parallel with netropsin and 
our compounds to provide another control.  As well as being positive controls, it is 
interesting to see how our amino acid-benzimidazole-amidine conjugates compare to 
netropsin and distamycin since they were principal molecules in the design of our 
conjugates. 
 
3.3. HT-FID Analysis of Amino Acid-Benzimidazole-Amidine Conjugates 
 The HT-FID assay clearly provides a rapid approach to the detection of ligand-
DNA binding that is applicable to a wide range of structurally diverse ligands including 
peptide-derived agents such as netropsin and distamycin.  Thus, the assay is valuable in 
the examination of our amino acid-benzimidazole-amidine conjugates. 
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3.3.1. HT-FID Analysis of Mono-Amino Acid-Benzimidazole-Amidine Conjugates 
 To determine the relative binding affinity of our mono-amino acid-benzimidazole-
amidine conjugates to that of our model-benzimidazole and model-benzimidazole-
amidine compounds (as well as netropsin and distamycin), all of the compounds were 
analyzed with the FID assay using CT-DNA.  Figure 3.2 shows the merged-bar 
histogram of 0.75 µM, 1.50 µM, and 3.00 µM concentration of our mono-amino acid-
benzimidazole-amidine conjugates.  The graph shows that the two well-known DNA-
binding agents, netropsin and distamycin, exhibit better binding than any of the mono-
amino acid-benzimidazole-amidine conjugates.  While the positively charged arginine-
containing conjugate is present in the top five of our novel compounds in this assay, the 
conjugate containing lysine does not appear near the front of the graph, and in fact 
shows similar binding to the model compound without an amidine group present.  This is 
a surprising result given their similar charged nature, the added positive charge of these 
two side chains would aid in delivering conjugates containing arginine and lysine to 
DNA. 
 
 
 
Figure 3.2. Relative binding of Xaa-BI-(+) conjugates in CT-DNA. 
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3.3.2. HT-FID Analysis of Dipeptide-Benzimidazole-Amidine Conjugates 
 We also determined the relative binding affinity of our dipeptide-benzimidazole-
amidine conjugates using the FID assay in comparison to netropsin, distamycin, model-
benzimidazole, and the model-benzimidazole-amidine compounds.  The results of the 
experiment using 0.75 µM, 1.50 µM, and 3.00 µM concentrations of the dipeptide 
conjugates are shown in Figure 3.3.  Initially, the compound that presented the best 
binding to CT-DNA was the cysteine-containing dipeptide-benzimidazole-amidine, Cys-
Gly-BI-(+).  This conjugate even outperformed netropsin, which was a very surprising 
result.  There was a suspicion that perhaps the conditions of the assay were causing the 
sulfur of cysteine to oxidize and form a sulfone or sulfoxide.  A sample of the reaction 
mixture was removed an analyzed by LC/MS, yielding a peak of +16 (m/z 456) which 
suggests that a sulfoxide was forming on cysteine, thus altering our conjugate’s binding 
ability, perhaps in an advantageous fashion. 
 
  
 
Figure 3.3. Relative binding of Xaa-Gly-BI-(+) conjugates in CT-DNA. 
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 In analyzing our relative binding results, four of our conjugates, Lys-Gly-BI-(+), 
Phe-Gly-BI-(+), Met-Gly-BI-(+), and Tyr-Gly-BI-(+) presented stronger binding than 
distamycin with Arg-Gly-BI-(+) being a slightly less potent binder than distamycin.  Out of 
this subset, Lys-Gly-BI-(+) and Arg-Gly-BI-(+) are conjugates that we expected to 
present strong binding in large part due to their positively charged side-arms.  The large 
planar aromatic rings of Phe-Gly-BI-(+) and Tyr-Gly-BI-(+) can also insert into DNA,11 so 
their presence at the front of the histogram is not surprising.  Methionine-containing 
peptides have also been shown to enhance DNA cleavage12 which may explain the 
presence of Met-Gly-BI-(+) near the front of the histogram and its outperforming the well-
known binder, distamycin.  
 After our initial results, we sought to further analyze the compounds which 
presented the best binding.  We also included Gly-Gly-BI-(+) in the analysis since it is 
the most elementary of our conjugates as a comparison.  The results of the further 
analysis of the conjugates at  0.75 µM, 1.50 µM, 2.25 µM, 3.00 µM, 3.75 µM, and 4.50 
µM concentrations is shown in Figure 3.4. 
 
  
 
Figure 3.4. Focused relative FID binding analysis of the most potent binders. 
0 %
10 %
20 %
30 %
40 %
50 %
60 %
70 %
80 %
90 %
100 %
P
e
rc
e
n
t 
Fl
u
o
re
sc
e
n
ce
 
Relative Binding of the Focused  
Xaa-Gly-BI-(+) Conjugates 
0.75uM
1.50uM
2.25uM
3.0uM
3.75uM
4.50uM
75 
 
Upon further analysis, netropsin and distamycin present the strongest DNA-
binding ability as expected and the two conjugates containing positively-charged side 
arms, Lys-Gly-BI-(+) and Arg-Gly-BI-(+), have the strongest binding of all our 
conjugates.  The presence of lysine- and arginine-containing conjugates at the front of 
the histogram, outperforming all of our other dipeptide-conjugates is expected as they 
both contain a positively charged side-arm that should aid in delivering the conjugate to 
A/T-rich regions of DNA.  It is possible that our initial analysis did not show these 
expected results due to an operator error in addition of the compounds to the well or that 
over the course of the incubation, the conjugates were oxidized as seen with Cys-Gly-BI-
(+) or they decomposed in some manner, skewing the expected results. 
 
3.4. Summary 
 The dipeptide-benzimidazole-amidine conjugates appear to have better DNA-
binding ability than the mono-amino acid-benzimidazole-amidine conjugates as a couple 
of these conjugates actually outperformed distamycin in the FID assay.  Upon further 
review, it does appear that both netropsin and distamycin are superior to any of our 
conjugates, as is expected.  However, having conjugates that even come close to the 
DNA binding ability of these two compounds speaks to the great power of the amino 
acid-benzimidazole-amidine system and may warrant further synthesis and analysis to 
find stronger dipeptides and possibly tripeptides.  It also needs to be noted that the 
assay using CT-DNA only shows relative binding compared to each other compound 
and in no way shows site preference since CT-DNA is made up of a mixture of possible 
base-pair sequences.  Also, CT-DNA is a mixture of A/T base-pairs to G/C base-pairs, 
thus the known A/T-binders netropsin and distamycin will only be able to bind to a 
portion of the available DNA.  This may also apply to our conjugates as they are 
designed to be A/T-binders, but further analysis of the site-selectivity of each conjugate 
will be needed and is beyond the scope of the analysis that we intended to perform. 
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3.5. Experimental Protocols 
 
3.5.1. Materials 
 Netropsin (ε296 = 21,500 M
-1cm-1) and distamycin (ε303 = 37,000 M
-1cm-1) were 
purchased from Sigma-Aldrich and quantitated spectroscopically and materials used in 
buffer solution, NaCl and tris(hydroxymethyl)-aminomethane (TRIS), were also 
purchased from Sigma-Aldrich.  Ethidium bromide (ε476 = 5680 M
-1cm-1) was purchased 
from Fluka and quantitated spectroscopically.  Calf thymus DNA (ε260 = 6300 M
-1cm-1) 
was purchased from Invitrogen and the concentration of the CT-DNA was confirmed by 
ultraviolet-visible spectroscopy.  All amino acid-benzimidazole-amidine conjugates were 
synthesized through previously detailed solid-phase protocols in our laboratory.  All 
experiments were carried out on a Varian Cary Eclipse Spectrophotometer fluorescence 
plate reader. 
 
3.5.2. HT-FID Assay 
 Each well of a Costar black 96-well plate was loaded with TRIS buffer along with 
ethidium bromide (150 μL of 5.5 μM EtBr, 120 mM NaCl, and 12 mM TRIS).  Calf 
thymus DNA was then added to each well (25 μL of 11.1 μM CT-DNA in H2O).  Final 
concentrations in each well were 1.5 μM CT-DNA, 4.5 μM EtBr, and 0.75 to 3.00 μM of 
DNA-binding agent.  The final buffer solution consists of 100 mM NaCl, 10 mM TRIS, pH 
7.4.  After incubation at 25 °C for 30 minutes, each well was read (average of three 
readings) on the fluorescence plate reader (λEx 545 nm, λEm 595 nm).  Compound 
assessments were conducted in triplicate with each well acting as its own control well 
(no agent = 100% fluorescence, no DNA = 0% fluorescence) and fluorescence readings 
are reported as a percent fluorescence decrease relative to the control wells.   
 The above protocol was followed for the focused analysis of dipeptide-
benzimidazole-amidine conjugates except for the range of compound concentrations 
was 0.75 to 4.50 μM. 
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Appendix A.  1H NMR Spectra 
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Appendix B.  Mass Spectra 
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